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A principal goal of precision medicine is to identify genomic factors that are predictive of 
outcomes in complex diseases, to provide better insight into their molecular mechanisms. Based 
on our current understanding, there are many genomic factors that are likely to be pathogenic in 
small subpopulations while being rare in the population as a whole. This research introduces a 
new machine learning method for discovering single nucleotide variants (SNVs), both common 
and rare, that in a given person are predictive of that person developing a disease or disease 
outcome.  
The new method described in this research constructs decision tree models, uses a 
Bayesian score to evaluate the models, and employs a person-specific search strategy to identify 
SNVs that are predictive in a subpopulation whose members are similar to the person of interest. 
This method, called the Personalized Decision Tree Algorithm (PDTA), works by constructing a 
decision tree model from the data and then identifying a path in the tree that has excellent 
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prediction for the person of interest, or constructing a new path if none of the paths in the tree 
have excellent prediction. 
The PDTA was refined iteratively on synthetic data and was experimentally evaluated on 
five datasets. One of the datasets was synthetic, one was semi-synthetic, and three were 
biological datasets collected from patients with chronic pancreatitis that included one small 
genomic dataset, a whole exome dataset, and a whole exome dataset focused on patients with 
diabetes in chronic pancreatitis. The performance of the method was evaluated using area under 
the Receiver Operating Characteristic curve and F1 score, as well as the ability to retrieve known 
and unknown rare SNVs. The PDTA was found to be effective to varying degrees in the datasets 
that were evaluated, creating parsimonious genetic representations for patient-specific groups, 
with the potential to discover novel variants. 
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TABLE OF CONTENTS 
ACKNOWLEDGEMENTS .................................................................................................... XIV 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 OVERVIEW OF THE PDTA ............................................................................. 2 
1.2 HYPOTHESIS AND AIMS OF THE DISSERTATION ................................. 3 
1.3 INNOVATION ..................................................................................................... 4 
1.4 OVERVIEW OF THE DISSERTATION ......................................................... 4 
2.0 BACKGROUND .......................................................................................................... 5 
2.1 GENOMIC BASIS OF DISEASE ...................................................................... 5 
2.2 PRECISION MEDICINE FOR COMPLEX DISEASES ................................ 8 
2.3 CHRONIC PANCREATITIS AS A CASE STUDY......................................... 9 
2.4 MACHINE LEARNING METHODS .............................................................. 11 
2.4.1 Instance-based Machine Learning ............................................................... 12 
2.4.2 Decision trees.................................................................................................. 13 
2.4.2.1 Lazy decision trees .............................................................................. 15 
2.4.2.2 Probabilistic decision trees ................................................................. 15 
2.4.3 Patient-specific models .................................................................................. 17 
3.0 ALGORITHMIC METHODS .................................................................................. 19 
3.1 NOTATION AND DEFINITIONS .................................................................. 20 
 vii 
3.2 STANDARD DECISION TREE (SDT) ........................................................... 23 
3.2.1 SDT model ...................................................................................................... 23 
3.2.2 Description of SDTA ..................................................................................... 25 
3.2.2.1 Structure Prior .................................................................................... 26 
3.2.2.2 Bayesian score: BDeu .......................................................................... 27 
3.2.2.3 Search Strategy ................................................................................... 28 
3.2.3 Example of SDT model.................................................................................. 30 
3.3 PERSONALIZED DECISION TREE (PDT) ................................................. 31 
3.3.1 PDT model ...................................................................................................... 31 
3.3.2 Description of PDTA ..................................................................................... 33 
3.3.2.1 Model score .......................................................................................... 33 
3.3.2.2 Search strategy .................................................................................... 34 
3.3.3 Example PDT model ...................................................................................... 36 
4.0 EXPERIMENTAL METHODS ................................................................................ 38 
4.1 DATASETS ........................................................................................................ 38 
4.1.1 Synthetic Dataset (SD)................................................................................... 39 
4.1.2 Small Biological Dataset (SBD) .................................................................... 40 
4.1.3 Semi-Synthetic Dataset (SSD)....................................................................... 40 
4.1.4 Whole Exome Chronic Pancreatitis (WE-CP) ............................................ 41 
4.1.5 Whole Exome Pancreatitis with Diabetes (WE-DB) .................................. 41 
4.2 PERFORMANCE METRICS .......................................................................... 42 
4.2.1 Area under the ROC curve (AUC) .............................................................. 42 
4.2.2 Minimal Split Ratio (MSR) ........................................................................... 43 
 viii 
4.2.3 Causal variable detection .............................................................................. 43 
4.3 GENE AND VARIANT INFORMATION ...................................................... 44 
4.3.1 PDTA conventions ......................................................................................... 44 
4.3.2 Tools and Databases ...................................................................................... 45 
4.4 COMPARISON ALGORITHMS..................................................................... 45 
4.4.1 Regular decision tree ..................................................................................... 45 
4.4.2 K2 Bayesian score .......................................................................................... 46 
4.4.3 Akaike Information Criterion (AIC) ........................................................... 46 
4.4.4 Minimum Description Length (MDL) score ............................................... 46 
5.0 EXPERIMENTAL RESULTS .................................................................................. 47 
5.1 EVALUATION AND ITERATIVE REFINEMENT OF PDTA ON SD ..... 47 
5.1.1 Empirical Optimization of PDT on SD ........................................................ 48 
5.1.2 Refinements to improve generalization ....................................................... 55 
5.1.3 Refinements for genetic models .................................................................... 63 
5.1.4 Conclusions .................................................................................................... 66 
5.2 EVALUATION OF PDTA ................................................................................ 67 
5.2.1 Evaluation of refined PDTA on SBD ........................................................... 68 
5.2.1.1 Empirical Optimization of PDT on SBD ........................................... 68 
5.2.1.2 Model Assessment on SBD ................................................................. 73 
5.2.1.3 Summary of PDTA performance on SBD ......................................... 75 
5.2.2 Evaluation of refined algorithm on SSD ..................................................... 75 
5.2.2.1 Empirical Optimization of PDT on SSD ........................................... 75 
5.2.2.2 Model assessment on SSD ................................................................... 81 
 ix 
5.2.2.3 Summary of PDTA performance on SSD ......................................... 81 
5.2.3 Evaluation of refined algorithm on WE-CP ............................................... 82 
5.2.3.1 Empirical Optimization of PDT on WE-CP and WE-CPR ............ 82 
5.2.3.2 Model assessment on WE-CP-R ........................................................ 84 
5.2.3.3 Summary of PDTA performance on WE-CP-R ............................... 95 
5.2.4 Evaluation of refined algorithm on WE-DB ............................................... 95 
5.2.4.1 Empirical Optimization of PDT on WE-DB ..................................... 95 
5.2.4.2 Model assessment on WE-DB ............................................................ 97 
5.2.4.3 Empirical Optimization of PDT on WE-DB-R ................................. 99 
5.2.4.4 Model assessment on WE-DB-R ...................................................... 101 
5.2.4.5 Summary of PDTA performance on WE-DB and WE-DB-R ....... 104 
5.2.5 Comparison to other methods .................................................................... 105 
6.0 CONCLUSIONS ...................................................................................................... 106 
6.1 FINDINGS AND CONTRIBUTIONS ........................................................... 108 
6.2 FUTURE WORK ............................................................................................. 108 
6.2.1 Dimensionality Reduction ........................................................................... 108 
6.2.2 Genotypic specificity.................................................................................... 109 
BIBLIOGRAPHY ..................................................................................................................... 110 
 x 
LIST OF TABLES 
 
Table 1: Summary of datasets ....................................................................................................... 39 
Table 2: Resources for gene and variant information ................................................................... 45 
Table 3: Hyperparameter settings used in SDTA on SD .............................................................. 48 
Table 4: 10 best SDTs on SD, ranked by lowest MSR ................................................................. 49 
Table 5: Results of PDTA on SD with best SDT parameters ....................................................... 50 
Table 6: Paths selected from SDT1 by SD test instances, ranked by frequency .......................... 54 
Table 7: 10 best SDTs on SD with termination rule, ranked by lowest MSR .............................. 60 
Table 8: 10 best SDTs on SD with pruning, ranked by lowest MSR ........................................... 60 
Table 9: 10 best SDTs on SD with pruning and genotype adaptation, ranked by lowest MSR ... 66 
Table 10: Results of PDTA on SD with pruning and genotype .................................................... 66 
Table 11: Hyperparameter settings used in SDTA on SBD ......................................................... 68 
Table 12: 10 best SDTs on SBD, when ranked by lowest MSR ................................................... 72 
Table 13: 10 best SDTs on SBD, when ranked by highest AUC ................................................. 72 
Table 14: Results of PDTA on SBD with best SDT parameters by MSR .................................... 74 
Table 15: Results of PDTA on SBD with best SDT parameters by AUC .................................... 74 
Table 16: Hyperparameter settings used in SDTA on SSD .......................................................... 76 
Table 17: 10 best SDTs on SSD, when ranked by highest AUC .................................................. 77 
 xi 
Table 18: SDT paths selected by test samples of SSD, ranked by frequency .............................. 80 
Table 19: Hyperparameter settings used in SDTA on WE-CP ..................................................... 83 
Table 20: Hyperparameter settings used in SDTA on WE-CP-R ................................................. 83 
Table 21: 10 best SDTs on WE-CP-R, ranked by highest AUC .................................................. 84 
Table 22: Results of PDTA on WE-CP-R with best SDT parameters .......................................... 84 
Table 23: Top 8 SDT paths selected by test samples of WE-CP-R (out of 110) .......................... 86 
Table 24: SNVs in SDT_Path1 on WE-CP-R............................................................................... 89 
Table 25: SNVs in SDT_Path2 on WE-CP-R............................................................................... 91 
Table 26: SNVs in SDT_Path3 on WE-CP-R............................................................................... 92 
Table 27: SNVs in SDT_Path4 on WE-CP-R............................................................................... 93 
Table 28: SNVs in SDT_Path5 on WE-CP-R............................................................................... 94 
Table 29: Hyperparameter settings used in SDTA on WE-DB .................................................... 96 
Table 30: 10 best SDTs on WE-DB, ranked by highest AUC ...................................................... 96 
Table 31: Results of PDTA on WE-DB with best SDT parameters ............................................. 97 
Table 32: SDT paths selected by test samples of WE-DB, ranked by frequency ......................... 98 
Table 33: SNVs in SDT_Path1 on WE-DB .................................................................................. 99 
Table 34: Hyperparameter settings used in SDTA on WE-DB-R .............................................. 100 
Table 35: 10 best SDTs on WE-DB-R, ranked by highest AUC ................................................ 100 
Table 36: Results of PDTA on WE-DB-R with best SDT parameters ....................................... 101 
Table 37: Top 8 SDT paths selected by test samples of WE-DB-R (out of 31) ......................... 102 
Table 38: SNVs in SDT_Path1 on WE-DB-R ............................................................................ 103 
Table 39: PDTA performance compared to other methods ........................................................ 105 
 xii 
LIST OF FIGURES 
 
Figure 1. Schematic representation of terminology used in this dissertation ............................... 22 
Figure 2: Pseudocode for the SDTA ............................................................................................. 29 
Figure 3: Example SDT model ..................................................................................................... 31 
Figure 4: Pseudocode for PDTA ................................................................................................... 35 
Figure 5: Example PDT model ..................................................................................................... 37 
Figure 6: Example tree with two paths, node counts and edges. .................................................. 44 
Figure 7: Trend of SDTA on SD ................................................................................................... 51 
Figure 8: Trend of SDTA on SD, continued ................................................................................. 52 
Figure 9: PS paths generated by PDTA ........................................................................................ 55 
Figure 10: Trend of SDTA on SD with termination rule .............................................................. 57 
Figure 11: Trend of SDTA on SD with termination rule, continued ............................................ 58 
Figure 12: Trend of SDTA on SD with pruning ........................................................................... 61 
Figure 13: Trend of SDTA on SD with pruning, continued ......................................................... 62 
Figure 14: Trend of SDTA on SD with pruning and genotype adaptation ................................... 64 
Figure 15: Trend of SDTA on SD with pruning and genotype adaptation, continued ................. 65 
Figure 16: Trend of SDTA performance on SBD ......................................................................... 70 
Figure 17: Trend of SDTA performance on SBD, continued ....................................................... 71 
 xiii 
Figure 18: Trend of SDTA on SSD .............................................................................................. 78 
Figure 19: Trend of SDTA on SSD, continued............................................................................. 79 
Figure 20: Interrelation of the 5 patient subgroups highlighted in Tables 24-28 ......................... 87 
 xiv 
ACKNOWLEDGEMENTS 
 
I am grateful for the contributions of many people towards the accomplishment of this work. 
Foremost, I would like to express my deep gratitude to my thesis advisor, Shyam 
Visweswaran, who makes brilliance look so effortless. I was privileged to have his patient and 
insightful guidance as a student. The initial version of the algorithm at the heart of my 
dissertation was developed by Dr. Visweswaran along with Gregory F. Cooper, whom I also 
thank for his contributions to not only this work, but as a teacher and researcher at the 
Department of Biomedical Informatics (DBMI) at the University of Pittsburgh. The development 
of this algorithm benefitted from work done in early stages by Jose Posada Aguilar, Adriana 
Johnson, and Louisa Zhang. While a doctoral student, I received funding from the National 
Library of Medicine (NLM), and I am grateful for the experience this enabled from the entire 
community of students, staff and faculty at DBMI. 
My development as a graduate student was enriched by Michael J. Becich, whose 
mentorship opened my eyes to a vast world of opportunities in healthcare and helped me find my 
niche. I would also like to thank my committee members, David C. Whitcomb and Xinghua Lu, 
for their expertise. May I also pause a moment in memory of M. Michael Barmada, whose 
untimely passing was a great loss to our academic community. 
 xv 
The journey undertaken towards this dissertation included contributions from many in my 
personal life as well. I would like to thank my parents, Biplab and Susmita Dutta, whose 
intellectual curiosity, integrity and unconditional love have made me who I am today. I would 
also like to thank my parents-in-law, Sam and Cathie Moscato, whose unwavering support and 
sense of humor has sustained me over the years. I am grateful for the support and friendship of 
Sudeshna Dutta, Monika Woszczyna, Katrina Romagnoli and Rubaiya Amin. My son, Aritro A. 
Moscato, through whose eyes I get to see anew the wonder and beauty of the world, who 
reminds me constantly of the joy in discovery and creation. My husband, Michael J. Moscato, for 
his generosity and optimism; his partnership is the rock that gives me wings. 
 
 
 
 1 
1.0  INTRODUCTION 
Fundamental activities in medicine include assessing disease risk, making diagnoses, estimating 
prognoses, and selecting appropriate therapy for an individual patient. The emerging area of 
precision medicine takes the approach that accounting for differences within clinically defined 
populations allow doctors and researchers to more precisely define groups of patients for specific 
treatment and prevention strategies1. This approach is particularly encouraging for patients with 
complex diseases, such as chronic pancreatitis, where groups of patients with the same disease 
often exhibit a variety of both causal factors and emergent clinical features, implying diversity in 
their disease mechanism. A patient-based approach, which works within the context of the 
population-based knowledge of the disease, has the potential to enable 1) more accurate 
prediction of individual risk, 2) discovery of disease subtypes among subpopulations, and 3) 
identification of individual genomic, environmental and clinical factors that explain risk, 
diagnosis, or prognosis in the individual. The precision medicine approach is in contrast to a 
“one-size-fits-all” approach, in which disease prevention and treatment strategies are developed 
for an average person, with less consideration for the differences between individuals. 
In this dissertation, I present the development and evaluation of an algorithm for finding 
genetically defined subgroups within patient populations, the Personalized Decision Tree 
Algorithm (PDTA). 
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1.1 OVERVIEW OF THE PDTA 
Predictive modeling consists of two steps: learning, which trains a model from a database of 
individuals, and inference, which predicts an outcome for a given individual. If a model performs 
well at prediction, it can be examined to identify features that are relevant to the prediction.  The 
typical paradigm in predictive modeling consists of learning a single model from a database of 
individuals, which is then applied to predict outcomes for any future individual. Such a model is 
called a population-wide model because it is intended to be applied to an entire population of 
future individuals. In contrast, personalized modeling focuses on learning models that are 
tailored to the characteristics of the individual at hand. Personalized models that are optimized to 
perform well for a specific individual are likely to have better predictive performance than the 
typical population-wide models, which are optimized to have good predictive performance, on 
average, on all future individuals2. Moreover, personalized models have the potential to identify 
genomic, environmental and clinical factors that are specific to the individual for explaining risk, 
diagnosis or prognosis. Thus, personalized predictive models are likely to be useful in precision 
medicine. 
The goal of precision medicine is to map treatment and prevention strategies to specific 
groups of people in an evidence-based manner. I propose that the PDTA will enable prediction of 
patient subgroups characterized by a set of distinct predictive variables. PDTA uses a Bayesian 
score, which prioritizes combinations of variables that maximize the posterior probability of 
observed phenotype or outcome, and focuses the search for predictors around the known features 
of an individual. 
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1.2 HYPOTHESIS AND AIMS OF THE DISSERTATION 
I hypothesize that the incorporation of an individual’s genomic and clinical factors in building 
predictive models will lead to better predictions, and identification of factors relevant to clinical 
outcomes in that individual. Additionally, this approach will identify a subpopulation of 
individuals in the data who are most similar to the individual and identify an interpretable set of 
characteristics that defines the subpopulation.  
I also hypothesize that the personalized modeling approach will provide several 
advantages. It will enable the discovery of a parsimonious set of factors that are predictive for 
the individual for whom the model was developed. By building a Bayesian model that views 
each patient within a subpopulation of similar patients, we can discover rare genomic variants 
that are otherwise obscured in diverse patient populations.  
To test my hypothesis, I propose the following aims: 
 
Aim 1. Implement and extend a Personalized Decision Tree Algorithm (PDTA) to produce 
individualized predictions, uncover a subpopulation whose members are most similar to the 
individual at hand and identify relevant factors for the individual of interest, that include 
genomic factors. 
 
Aim 2. Evaluate PDTA and its extensions on synthetic, semi-synthetic and real genomic data 
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1.3 INNOVATION 
I have developed an algorithm that constructs personalized decision tree models based on the 
genomic factors of a specific individual. The algorithm uses a Bayesian score to evaluate models, 
and a personalized search strategy to identify high-scoring models. Unlike generic decision trees, 
which myopically choose splits based on best information gain at the local node, the PDTA 
considers the best score obtained over the entire model structure and parameter priors. The 
algorithm is also implemented to consider value merging to accommodate allelic combinations 
as seen in genotypic models. Models built with this algorithm present an interpretable and 
statistically sound way to analyze complex disease phenotypes to (1) discover rare variants in 
individuals, (2) discover subpopulations of individuals, (3) discover genetic signatures of 
subpopulations of individuals. In doing so, the algorithm improves our ability to develop 
personalized treatment and prevention, characterizing verifiable subpopulations within a 
heterogeneous disease population with a parsimonious set of predictive factors. 
1.4 OVERVIEW OF THE DISSERTATION 
In this section, I provide a brief overview of this dissertation. 
 Chapter 2 provides background relevant to the role of a personalized algorithm for 
genomics and precision medicine. Chapter 3, describes the algorithm and related theory. Chapter 
4 describes the datasets, performance metrics, information sources and conventions used in this 
dissertation. Chapter 5 describes the evaluation of PDTA on several different datasets. Chapter 6 
summarizes the findings and conclusions drawn from this work. 
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2.0  BACKGROUND 
This chapter provides an overview of genomics and precision medicine relevant to the 
application and utility of the PDTA, followed by machine learning background relevant to the 
development of the PDTA. Section 2.1 gives an overview of genomics and gene variants in 
disease. Section 2.2 covers the importance and goals of precision medicine. Section 2.3 gives an 
overview of chronic pancreatitis as a case study for the application of PDTA. Section 2.4 places 
the development of PDTA within the context of existing machine learning applications. 
 
2.1 GENOMIC BASIS OF DISEASE 
Over the past century, the classification of diseases based on causative genes has settled broadly 
into two types: Mendelian or monogenic diseases, and complex or polygenic diseases.  
Mendelian diseases, such as cystic fibrosis or sickle cell disease, are caused primarily by 
defect of a single gene, and tend to be rare in the general population. In this category of diseases, 
genomic sequencing of a small number of affected individuals may be sufficient to identify the 
causal variant and the associated gene. For example, Ng et al. sequenced the exome of four 
unrelated individuals with Freeman Sheldon syndrome (a rare inherited disorder) and eight 
healthy individuals, and were able to correctly identify the gene previously known to cause the 
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syndrome3. In a following study, Ng et al. sequenced the exomes of four individuals with Miller 
syndrome (a rare malformation disorder) and identified a new casual variant4. 
Complex diseases, involving disruption in several genes, occur more frequently in the 
population, and exhibit complex features in their etiology as well as expression. They are likely 
to be heterogeneous, with variants in a number of different genes, or have variants in multiple 
loci of the same gene, all manifesting in the same or similar phenotypes. Even though they may 
cluster in families, they do not necessarily have a clear pattern of inheritance. Many complex 
diseases – such as heart disease, type 2 diabetes, and cancer – are influenced by lifestyle and 
environmental factors. If multiple genomic causes manifest small and varied effects on disease 
expression, large samples of affected and healthy individuals are needed to identify the causal 
variants. For example, a meta-analysis of 74,046 individuals identified 19 variants associated 
with Alzheimer’s disease5. 
The simplest sequence variations in the DNA are the single nucleotide variants (SNVs). 
Classically, SNV referred to any variation in the DNA that may or may not have been well 
characterized, while an SNV with a minor allele frequency (MAF) exceeding 5% in the 
population was called a single nucleotide polymorphism (SNP). In recent years, however, the 
recognition of the value of rarer variants has led to the broadening of the term “SNP” to often be 
used interchangeably with the term “SNV”. For example, the National Center for Biotechnology 
Information (NCBI) database of short genetic variations, dbSNP, while initially built as a 
database of SNPs, has expanded to include single nucleotide substitutions even if they have not 
been found to occur frequently enough in a population to be termed polymorphic6. According to 
the rare variant hypothesis, a significant proportion of inherited susceptibility to chronic diseases 
may be due to the summation of the effects of a series of low frequency variants of a variety of 
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different genes, each conferring a moderate but readily detectable increase in relative risk7. Even 
if the frequency of a single variant is less than 5%, the collective power of numerous rare 
variants can raise disease association to a significant level. While disease-causing rare variants 
usually have MAF ranging from 0.1% to 3%, depending on the context, some have been found to 
have frequency lower than 0.01%8. 
Many pathogenic variants, as commonly sought in clinical genetic testing, have been 
discovered from genome wide association studies (GWASs)9. The paradigm of GWAS is based 
on the common disease-common variant hypothesis, which posits that disease-causing alleles are 
likely to be common gene variants that can be detected as statistically significant when 
comparing affected individuals with controls10. These variants alone often fail to provide a 
complete functional mechanism for the disease phenotype, and it has become increasingly clear 
that rare variants likely also play an important role in complex diseases, independently or in 
conjunction with other variants, common or rare11,12. Next generation sequencing methods such 
as whole exome sequencing provide a more complete set of rare and common variants from 
protein-coding regions (exons) of the DNA. Given this landscape, genomic causal mechanism 
can be broadly subdivided into three categories13: a large number of small-effect common 
variants across the entire allele frequency spectrum (the infinitesimal model)14,15, a large number 
of large-effect rare variants (the rare allele model)16 or some combination of genotypic, 
environmental and epigenetic interactions (the broad sense heritability model)17,18. Therefore, the 
development of statistical methods to detect rare variants with relevant effect sizes is crucial12. 
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2.2 PRECISION MEDICINE FOR COMPLEX DISEASES 
According to the National Institutes of Health (NIH), precision medicine is "an emerging 
approach for disease treatment and prevention that takes into account individual variability in 
genes, environment, and lifestyle for each person"1. With the rapid increase in data collection 
and the ability to analyze larger datasets in tractable time, it is feasible to prioritize a patient’s 
care to their individual needs. To unravel this potential, personalization of medicine requires two 
fundamental characterizations: a well-grounded understanding of who the patient is, and an 
equally robust understanding of the subpopulation that most resembles that patient, in the context 
of the decisions at hand. When these characterizations are represented probabilistically and can 
be used to drive decision-making in a rational manner, we can maximize the positive outcomes 
for the patient19. Next generation sequencing technologies provide detailed genomic information 
on each patient, but the clinical implications can only be realized when the results of genetic 
testing are actionable, thus informing prognosis or treatment20. With rapidly growing clinical 
databases and interoperability of electronic health records (EHRs), we get closer to being able to 
use genomic knowledge and clinical information to further enrich an actionable, personalized 
patient profile. 
With the existing use of evidence-based recommendations in clinical practice, 
personalization can be implemented by capturing subgroups whose members share the most 
salient features with a specific patient21,22. This is the idea behind endeavors such as future point-
of-service decision support scanning EHRs for patients with similar profiles23. The first reported 
use of querying medical records of past patients in near real-time to aid in treatment decision 
took place in 2011, when investigators at Stanford University searched for patients similar to a 
13 year old girl with lupus nephritis to decide on anticoagulation therapy24. Other patient 
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similarity analytics tools can incorporate predictive models of a patient's outcome that is trained 
from a subpopulation similar to the index patient25. 
The high dimensional data generated by next generation sequencing provide a 
comprehensive view of common and rare SNVs in a patient’s genomic profile, but the number of 
individuals comprising a cohort for study is usually small relative to the large number of SNVs 
to be assessed. In addition, if we are to uncover causal variants that are relevant only to a subset 
of patients, genetic signatures can appear to be highly variable across the tested populations, 
while showing patterns of similarity within subpopulations. The appropriate analysis methods 
should have the ability to make sound statistical judgments within the smaller sample sizes of 
subpopulations, and also be able to make use of the larger overarching phenotypic population, 
which is essentially the context that the smaller subpopulations are conditioned upon. Algorithms 
capable of discovering patient-specific subgroups based on their genomics dovetail with these 
goals of precision medicine, for both variant discovery as well as understanding the patient-
specific pathogenicity in an actionable framework26. 
2.3 CHRONIC PANCREATITIS AS A CASE STUDY 
Pancreatitis is an inflammatory condition of the pancreas. Repeated inflammatory damage, as 
recurrent acute pancreatitis (RAP) or chronic pancreatitis (CP), can lead to irreversible scarring 
and fibrosis of the pancreas, causing pain, incremental loss of function (leading to syndromes 
such as maldigestion and diabetes mellitus), and an increased risk of pancreatic cancer. The 
annual incidence of CP in industrialized countries is 3 to 10 per 100,000 population27. Although 
traditionally defined by a common clinical appearance and pathology, CP is a complex set of 
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disorders of heterogeneous etiology, involving a variety of signaling pathways, metabolic 
factors, and environmental susceptibilities28. Patients with CP often differ in their clinical course, 
symptomology and environmental risk factors.  
 Recent insights into the genetics of CP present a strong case for the role of precision 
medicine in guiding treatment of patients with CP29,30. The major CP causing genes are involved 
in trypsin control in the pancreas. A heterozygous pathogenic variant of the trypsinogen gene 
PRSS1, which results in autosomal dominant inheritance of pancreatitis, is found in 60%-100% 
of families with hereditary pancreatitis; non-PRSS1-related hereditary pancreatitis shows a 
different disease course, with a later age of onset31,32. Not all pathogenic mutations in PRSS1 
cause hereditary pancreatitis through the same mechanism; some, such as A16V exhibit variable 
penetrance, and can be seen with additional risk factors such as SPINK N34S to cause CP33. 
While the pathogenicity of PRSS1 A16V has been known for a while, another PRSS1 mutation, 
P17T was only discovered recently to mimic the effect of A16V34. Rare variants whose 
pathogenicity only occurs in the presence of other variants are difficult to discover through 
traditional association studies. 
Multiple other genetic risk factors are common, such as loss-of-function variants in 
CFTR and SPINK1, and various combinations of these genetic risk factors may be seen in 
different generations of one family35. A growing list of variants in other genes, such as CTRC, 
CASR, CLDN2, CPA1 have been emerging as well, with varying contributions to disease risk, 
along with variants that affect not only the coding sequences of proteins, but also their 
regulation29. The susceptibility to develop CP is also known to be increased by lifestyle factors 
such as smoking and alcohol use, with certain subgroups of patients showing a higher 
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susceptibility to these factors than others36. Correspondingly, studies have shown evidence of 
SNVs in PRSS1-PRSS2 and CLDN2 loci with high association to alcohol-related CP37. 
Genes such as PRSS1, SPINK1, CFTR and CTRC are commonly used in multigene panels 
to diagnose CP, although it is suspected that other common and rare variants are also risk factors 
in CP38,39. In the treatment and prevention of CP, it is important to uncover not only independent 
risk factors for the disease, but also factors that act synergistically and as modifiers of other risk 
factors. The genetic and clinical/behavioral risk factors characterizing a group of patients offer 
clues to the underlying disease mechanism malfunctioning in that group of patients and can steer 
treatment needs by anticipating the dysfunction specific to that patient’s biology. For example, 
damage to islet cells during the course of CP can give rise to diabetes in some CP patients40. 
Identifying genetic markers in the subgroup of patients prone to develop diabetes would open up 
the possibility of treatments specifically important for that subgroup of patients. A growing 
understanding of genetics and gene–environment interactions have led to clinical centers, such as 
at the University of Pittsburgh, classifying CP patients into general disease mechanism groups in 
their evaluation for pancreatic disease30. Improvements in personalization algorithms will 
support such endeavors. 
2.4 MACHINE LEARNING METHODS 
In building predictive models, a machine learning algorithm constructs a hypothesis space based 
on a finite set of observations, or instances. Generally speaking, the model is induced from these 
instances, known as the training dataset, and then used to infer outcomes on a separate set of 
instances, known as the test dataset. The best model – a combination of relational structure and 
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parameters to ‘explain’ an underlying mechanism that can generate this data – is built based on a 
scoring criterion to assess the likelihood of the training dataset from the model’s predictions. The 
value of prediction is then evaluated on a number of criteria, such as accuracy, generalizability 
and reliability, to make a claim on the suitability of the learning algorithm. 
The PDTA is most closely related to work categorized as instance-based learning. 
Section 2.4.1 covers the general area of instance-based learning. Section 2.4.2 focuses on a 
decision tree learning. Section 2.4.3 focuses on patient-specific machine learning. 
2.4.1 Instance-based Machine Learning 
Instance-based learning is a type of inductive learning method: simply put, it is learning by 
example. Unlike traditional classification methods, which learn from instances in the training 
data and then apply the model to test instances presented to it, instance-based learning methods 
incorporate test instances to create a model from training instances local to it41. It is often 
referred to as ‘lazy’ learning, since most of the computational work is not done upfront on the 
training dataset, but is done when the test instance becomes available. This constraint can cause a 
high computational load at runtime. However, these methods are useful for their ability to 
optimize locally around specific instances. 
There are three primary components to instance-based algorithms: (1) A similarity or 
distance function, which computes the similarity between instances used to identify instances in 
the training dataset that are near the test instance; (2) A classification function, which decides the 
locality specified for the test instance; (3) A concept description updater, which tracks the 
performance of the classification, and makes decisions on the choice of instances to include in 
the concept description. The k-nearest neighbor classification algorithm, in which a chosen 
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number, k, of the nearest neighbors of a classifier are used in order to create a local model for the 
test instance, is a canonical instance-based algorithm. Most instance-based algorithms derive 
from this concept. 
Other instance-based methods take advantage of the values of predictors to infer a class 
distribution within the locality of the test instance. This has been implemented by incorporating 
the instance-based approach in general classification methods such as decision trees and naïve 
Bayes. The LazyDT algorithm, described by Friedman et. al. (see Section 2.4.2.2) conceptually 
constructs the decision tree considered best for each test instance, and was shown to have better 
accuracy in predictions compared to population-wide decision tree methods such as ID3 and 
C4.542. The Lazy Bayesian Rules (LBR) learner, described by Zheng et. al., similarly modified a 
naïve Bayes model to search for the best model using the values of the predictors specific to the 
test instance, and was also shown to have superior performance when compared to a variety of 
population-wide methods43,44. This method was further extended by Visweswaran et. al. to 
perform Bayesian model averaging (BMA) over LBR models, and was shown to have higher 
accuracy on a range of datasets45. Other instance based algorithms that use Bayesian network 
models have also shown promise (see Section 2.4.3)2,46. 
2.4.2 Decision trees 
A decision tree, also known as a classification tree, is a predictive model that contains a 
branching structure of a tree. The tree consists of interior nodes, branches and leaf nodes. Interior 
nodes denote predictor variables, branches denoted values that a predictor can take, and all leaf 
nodes denote the target or outcome variable. An interior node denotes a test that is performed 
with a predictor, and each value that the predictor can take is denoted by a branch emerging from 
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the node. The root node at the top of the tree is an interior node that denotes the first predictor 
that is tested. Leaf nodes are terminal nodes that are found at the bottom of the tree; a leaf node 
denotes a decision or outcome and is represented by one value of the target variable. A path from 
the root to a leaf denotes a series of tests on predictors leading to a specific outcome at the leaf 
node. 
  The decision tree is a partitioning classifier: the tree partitions the input space into a set of 
non-overlapping regions, where each region corresponds to a distinct path in the tree. To 
construct a tree, decision tree methods usually employ a top-down, recursive, greedy divide-and-
conquer strategy. At every stage, the attribute most efficacious to classification of the 
observations is selected as predictor for the next step – a strategy termed “greedy” because it 
only considers the best option at the current step, without considering options that could lead to a 
better tree at some later stage. The structure and parameters for the tree are typically derived by 
recursive splitting to optimize a criterion such as error or entropy. Commonly used criteria for 
predictor selection include the Gini index, information gain, and misclassification error47. The 
goal is to construct a tree with the shortest paths, i.e. the shallowest possible tree, in a top-down 
manner. 
Each path in the tree defines a subpopulation of observed instances, and each member of 
the training dataset is assigned exactly one path in the tree. The test performed at each node of 
the decision tree is essentially an “if-then” rule, and a path in the tree is simply a conjunction of 
such rules terminating with a target at the leaf node. If-then rules and decision trees are 
expressive and human interpretable, and can capture both main effects and interactions among 
predictors. These qualities make decision tree models a popular choice for clinical decision 
making. 
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2.4.2.1 Lazy decision trees 
Friedman et.al. implemented an instance-specific (‘lazy’) version of decision trees which they 
called LazyDT42. The LazyDT considers the given test instance and derives a decision path 
guided by its features. Similar to generic decision trees, it uses a greedy approach to successively 
select features to add to the path, and uses information gain as its splitting criterion. At each step 
the LazyDT chooses a feature optimizing information gain at that node. After a feature is 
selected, only those individuals in the training dataset who match the features in the path derived 
so far are retained to derive the remaining part of the path. When compared to several decision 
tree methods including ID3, C4.5 without pruning, and C4.5 with pruning, LazyDT had higher 
predictive accuracy overall and performed substantially better than ID3 and C4.5 without 
pruning. Compared to C4.5 and CART, LazyDT handled missing values more naturally, but 
could be limited by the fact that it did not perform pruning, and hence could be susceptible to 
overfitting48. 
One of the key motivations for LazyDT was to avoid the undue influence of features that 
may dominate when training data is considered as a whole, but are irrelevant to the test instance 
at hand. A single tree built in advance can lead to many irrelevant splits for a given test instance, 
thus fragmenting the data unnecessarily. Such fragmentation reduces the significance of tests at 
lower levels since they are based on fewer instances. A decision tree built for the given instance 
can avoid splits on features that are irrelevant for the specific instance. 
2.4.2.2 Probabilistic decision trees 
In a probabilistic decision tree, each leaf node represents a probability distribution over the target 
variable. The tree can be converted into a set of if-then rules, wherein a path in the tree is 
translated into a probabilistic rule. Each rule has a conjunction of features in the antecedent, and 
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a probability distribution for the target in the consequent. When presented with a test case, the 
tree performs inference to identify a path such that the features in the path match the features in 
the test instance. The target probability distribution is estimated from the known outcomes of 
observed instances whose features matched the features in the identified path. Decision trees are 
very well suited to implementing Bayesian models, where we seek to reduce uncertainty as 
‘beliefs’ that can be updated as more data becomes available. Bayesian scores tend towards 
simpler structure, but as the model sees more data, it is willing to recognize that a more complex 
structure is necessary; it is good at trading off fit-to-data for lower model complexity, thereby 
reducing the extent of overfitting49. Learning decision trees as a Bayesian network was well 
developed by researchers near the turn of the century, and has gone on to form the foundation for 
Microsoft’s proprietary Decision Trees Algorithm to learn causal interaction models by 
obtaining approximate posterior distributions50-52. 
Buntine first described a Bayesian approach to learn probabilistic decisions trees from 
data53. He developed an algorithm to search and identify the tree with the maximum posterior 
probability, using the Bayesian Dirichlet (likelihood) equivalent uniform (BDeu) score to 
maximize the posterior probability of the tree structure. While BDeu has been a popular scoring 
choice for model selection criterion, especially in cases with no prior knowledge, it requires the 
selection of an equivalent sample size (ESS) hyperparameter, which reflects the degree of prior 
belief one would have needed to be confident about the given choice of Dirichlet prior 
parameters50. There is no generally accepted rule for determining the correct assignment of ESS. 
The value of ESS controls how much smoothing occurs in estimating probability parameters. 
Empirical studies have shown that the network structure is very sensitive to the choice of ESS; 
when the chosen value of ESS was reduced, for increasing sample size, simpler network 
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structures tended to be selected; when ESS became large, the number of arcs in the structure 
usually increased54,55. An asymptotic analysis of the BDeu score showed a monotonic increase in 
arcs added to the network structure as the ESS increases56. When using the BDeu score, it is 
important to test for its influence on the resultant model.  
2.4.3 Patient-specific models 
Patient-specific modeling can refer to a broad and diverse set of computational methods, all of 
which aim to improve personalization of healthcare. The idea of treatment schemes applied 
across subgroups of patients – also called stratified medicine57 – is not a new one. Some of the 
significant barriers to realizing the full potential of personalized medicine are issues of data 
collection and harmonization. I will not discuss these issues. My focus is on the analysis of this 
data to uncover rare variants with significant association with patient subgroups. 
One way to personalize for patient-based discovery is by building local models for a 
subset of the problem space, to be applied to patient subgroups. An example is patient-specific 
prediction for cancer survival58. Commonly used survival plots (using the Kaplan-Meier 
estimator) attempt prediction by aggregating individual patient characteristics. By implementing 
a local regression method for learning patient-specific survival time distribution based on all 
available patient attributes, Lin et. al. were able to improve the accuracy of survival predictions 
on a cohort of cancer patients. 
In contrast to such local modeling methods, personalized models have an element of 
computation “on the fly” for every new input vector (as characterized by instance-based 
approaches, Section 2.4.1), to generate an individual model based on the closest data instances to 
the new instance taken from a dataset59. These can employ the use of similarity metrics, as done 
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in one study to predict patient-specific risk profiles60. Ng et. al. developed a trainable similarity 
metric to find clinically similar patients, then created personalized risk factor profiles by 
analyzing the parameters of the trained personalized models. Another way to use a patient-
specific heuristic was demonstrated by Visweswaran et al, averaging over a set of Markov 
blanket models48. Both studies found that the personalized models gave better predictions than 
population-trained models. 
Using decision trees to build personalized models is essentially the task of creating a 
decision path customized to the features of a patient. Since decision trees are comprised of non-
overlapping series of nodes, a path identified as best match for a patient defines a subpopulation 
in the data, and each member of a dataset assigned to the tree is assigned to exactly one path. 
Previous work in creating personalized decision paths has shown promising results48,61. While 
those models were mostly focused on developing good predictive models, the PDTA is focused 
on uncovering variants that may be rare in the general population, but have relevance to 
predicting disease state within a subpopulation of similar patients. 
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3.0  ALGORITHMIC METHODS 
This chapter describes the PDTA that derives a personalized decision tree model. Briefly, the 
first phase builds a tree from the full population of patients, implementing what I call the 
standard decision tree algorithm (SDTA). The next phase implements the PDTA, personalized to 
a single patient, to custom-build a tree (which is just a path) for the patient. For ease of 
exposition, I will first describe the SDTA in detail and then I will explain how the PDTA builds 
on the SDTA and differs from it. After a summary of the main ideas underpinning the two 
algorithms, a detailed description follows. 
The goal of both the SDTA and PDTA is to optimally predict a discrete target (or class) 
variable, such as a clinical outcome, from a moderately large number of predictors such as 
genomic variants and other clinical factors. The SDTA derives a probabilistic decision tree 
model that I term the standard decision tree (SDT) model, and the PDTA learns a personalized 
probabilistic decision tree model that I call the personalized decision tree (PDT) model. Since 
these are decision tree models, each path in the model implicitly defines a disease-specific group 
of factors that characterize a subpopulation of individuals. If we use genomic variants as 
predictors for the model, the group of variants comprising a path serves as the genetic signature 
for a specific subpopulation. Given a person P, PDTA identifies a personalized path that 
represents a subpopulation of individuals from the training dataset who are genetically similar to 
P at a small number of loci. 
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The SDT is a decision tree that has class probabilities (i.e., a probability distribution for the 
prediction) at its leaf nodes, and paths in the tree that can be interpreted as probabilistic rules. 
The SDT is an example of a population model that is derived from a group of patients (each 
patient represented as an instance in a training dataset), and is applied to predict the outcome for 
any future patient. The PDT model consists of a combination of a decision tree and a patient-
specific (PS) path, where the path is tailored to the characteristics of the patient (an instance 
chosen from the test dataset) whose outcome is being predicted, and the decision tree is an 
alternate model for others who are not similar to the chosen patient. Personalized models that are 
optimized to perform well for a specific individual can identify features such as genomic factors 
that are specific for an individual, even if the factors are not common enough to reach statistical 
significance in a population-wide search, thus enabling precision medicine and the search for 
rare variants. 
3.1 NOTATION AND DEFINITIONS 
In the following exposition, random variables are denoted by italicized uppercase letters, such as 
X and Y. Instantiations of random variables are denoted by corresponding italicized lowercase 
letters, x and y. Vectors of variables are denoted by bold uppercase letters, such as X, Y, and their 
instantiations denoted by bold lowercase letters x and y. A feature is a specification of a variable, 
denoted as a variable-value pair. Thus, X = x is a feature that specifies that variable X is assigned 
the value x; X = x is a feature vector that specifies that the variables in X = (X1, X2, … , Xi, … , 
Xm) have the values given by x = x1, x2, … , xi, … , xm.  
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The dataset D = (X, Y) contains observations on m predictor variables X and one target 
variable Y, for n individual patients, and is comprised of a set of patients d1, d2, … , di, … , dn. 
The ith patient, di = (xi, yi) = (xi1, xi2, …, xim, yi) is instantiated by the observations on the 
predictors and the target for that patient (Figure 1 (a)). A model is derived from a training dataset 
D that contains values for X and Y. A model is typically evaluated on a test dataset Dtest that is 
distinct from the training dataset and consists of a set of test instances. In the case of the SDTA, 
only D is used to derive the model, which is then applied to the values of X in the test instance to 
predict a value of Y. In the case of PDTA, D is used along with the values of X in the test 
instance to derive the model, which is then applied to the values of X in the test instance to 
predict a value of Y. 
Both the SDT and PDT models use decision trees, modeled as M = (T, θ), where T 
denotes the model structure and θ is a parameter vector for the probability distributions over 
target Y. If L is the number of leaf nodes in T, then T consists of L paths R = R1, R2,…,Rl … , RL 
with parameter vector θl = (θl1, θl1,…, θlk, …, θlK), where K is the number of values Y can take 
(Figure 1(b)). Path Rl consists of a conjunction of J features X1 = x1 ^ X2 = x2 ^ Xj = xj. . . ^XJ = xJ 
where the predictor list XR = (X1, X2, . . ., Xj, . . ., XJ) is a subset of variables X in the domain and 
the list xR = (x1, x2,. . ., xj,. . ., xJ) is the list of corresponding values. 
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Figure 1. Schematic representation of terminology used in this dissertation 
(b) 
(a) 
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3.2 STANDARD DECISION TREE (SDT) 
This section provides a detailed description of the SDT model, and then describes the SDTA that 
uses a Bayesian approach to learn the optimal SDT from a dataset D. This is essentially a search 
for a decision tree structure with a high posterior probability, given the observations in D. The 
SDTA employs a score-and-search approach where a scoring metric (or score, for short) is 
adopted to evaluate candidate tree structures, while a heuristic search strategy is used to find a 
tree structure with the best score. For computational efficiency, a heuristic search is employed 
instead of an exhaustive search of the model space of the tree62. 
3.2.1 SDT model 
I will first describe the components of the SDT model in terms of structure (the graphical 
relationships), parameters (computation of probabilities) and inference. I will then discuss the 
Bayesian score to compute the parameters for best model that fits D. This is followed by a 
section describing how the model is used to perform inference for a test instance. 
 
Model structure and parameters. An SDT model M = (T, θ) has the structure T and the 
vector of parameters θ. The structure T has L leaf nodes, and a set of paths R. The size of θ is 
determined by the number of parameters K of the multinomial distribution  𝑃(𝑌|𝑿𝑹𝒍 =  𝒙𝑹𝒍)  over 
the target variable Y conditioned on 𝑿𝑹𝒍 = 𝒙𝑹𝒍 . (Each conditional probability distribution is a 
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multinomial; K is the number of values Y can take.) The values for θlk = (θl1, θl2,. . ., θlk,. . ., θlK) 
at each leaf are estimated from individuals in the training dataset D that satisfy 𝑿𝑹𝒍 = 𝒙𝑹𝒍 , using 
the BDeu score. 
 
Parameter estimation. The parameters are estimated in a Bayesian manner. The 
estimate for parameter θlk is given by the expectation (mean) of the posterior probability 
distribution of the parameter given data: 
 
 
 
 where  is the number of individuals in the training dataset D that satisfy  = ;  
is the number of individuals that satisfy  =  and Y = k;  is a parameter prior that can be 
interpreted as belief equivalent to having previously (prior to obtaining D) seen that  
individuals satisfy  and Y = k;  and . 
The parameter α is the priori equivalent sample size, or ESS, as discussed earlier for 
BDeu score. This parameter controls how much smoothing occurs in estimating probability 
parameters: the higher the value of α, the greater the smoothing that occurs.  
 
 Inference. Given a test instance Xtest = xtest, the parameterized model M is used to 
compute the probability distribution over the target variable Ytest of the test instance. Inference is 
performed by identifying the relevant path Rtest that fits the test instance’s features, and then the 
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parameters in the leaf node of Rtest are returned. Identification of the relevant path is done by 
sequentially identifying the outbound branch at each interior node, starting at the root node, by 
the value of the predictor associated with the node in the test instance. 
3.2.2 Description of SDTA 
The SDTA employs a heuristic search-and-score approach: In each iteration, every leaf node in 
the tree is examined for the possibility of replacing it with an interior node corresponding to a 
predictor variable that has not already been used. The tree with this replacement is evaluated by a 
score, as a measure of how well the tree represents the distribution the data was drawn from. 
Given the data D, the score of tree T is a measure of how probable the structure T is, over 
all possible parameterizations of T. It can therefore be calculated by the posterior probability: 
 
For a fixed dataset D, P(D) is constant, hence we can consider the score as: 
 
In this score, the term P(T) refers to the prior distribution over the structure T, hence 
known as the structure prior, described in Section 3.2.2.1. The term P(D|T) captures the posterior 
probability of the data given a particular parameterization of T. I use the Bayesian scoring 
function BDeu to optimize for this posterior term, described in Section 3.2.2.2. The numbers 
involved in Equation 2 can become very small, so computation is done in log space to avoid 
underflow. Following the derivations of the structure prior (Equation 5) and BDeu score 
(Equation 9) we get: 
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3.2.2.1 Structure Prior 
The term P(T) the denotes the prior distribution over the structure T.   I assume a binomial prior 
with uniform probability: 
 
where S is the subset of variables in D that are in T. For computational ease, I calculate 
this in log space: 
 
We can incorporate intuition from a domain expert through the structure prior. Let q be 
the expected number of predictors (ENP) in D that a domain expert expects to be predictive of Y. 
Since the total number of variables in D is m, a simple binomial prior is given by pi = q / m  when 
i S, and otherwise pi = 1 - (q / m). Further information on the effect of variables can be 
incorporated by replacing the uniform p with informative scores. 
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3.2.2.2 Bayesian score: BDeu 
The best model is one which not only maximizes the probability of generating the observed data, 
but also fits the unobserved data in the full distribution from which the observations are sampled. 
A good scoring function, therefore, should be asymptotically correct: the learned distribution 
with maximum score should converge (with high probability) to the underlying distribution, as 
the size of the data increases. 
Considering θ as the full set of parameterizations for T, the joint probability can be 
marginalized over all choices of θ: 
 
Applying the chain rule: 
 
Since P(T) is not dependent on θ, this can be moved outside of the integral: 
 
Since P(T, D) = P(D|T)∙P(T), dividing both sides by P(T) gives the marginal likelihood: 
 
The first term in the integral, P(D | T, θ), is the likelihood of the data D given structure T. 
For the second term, P(θ | T), if I assume a Dirichlet probability density function that specifies a 
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parameter prior distribution over θ, the marginal likelihood has a closed form solution (derived 
in Heckerman et al 1995 50: 
 
where  is the gamma function; K is the number of values of Y; L is the number of leaf 
nodes in T; Nlk is the number of individuals in D that satisfy the tests in path Rl and Y = k;  is 
the parameter prior ESS where  is a set {  ,  , … , };  and . 
For computational ease, I calculate this in log space: 
 
3.2.2.3 Search Strategy 
The space of tree structures is very large; an algorithm that examines every tree structure to 
identify the highest-scoring tree is computationally intractable except for very small values of m. 
Thus, heuristic search methods are appropriate for searching this model space. The SDTA uses 
greedy search to identify a high scoring model.  Because greedy search is not guaranteed to be 
optimal, SDTA is not guaranteed to find the best scoring model in the model space. However, in 
practice, greedy search performs well and identifies an excellent scoring tree structure. 
 29 
The pseudocode for growing the SDT is given in Figure 2. It follows a general process 
laid out in Buntine (1992)62. In each iteration, every leaf node is examined for the possibility of 
replacing it with an interior node corresponding to a predictor variable that has not already been 
used. The replacement that best improves the score (Equation 3) over the current tree is chosen; 
the node is added, extending the tree by one level. If no replacement can be found that improves 
the score of the current tree, the search terminates and the current tree is returned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SDTA (X, D) 
 Input:  X is a set of predictor variables 
     D is a training dataset of individuals described using X, a set of predictor 
      variables, and target variable Y 
 Output:  Tree   
 
 1 Tree = null  
 2 free_X = list of all predictor variables 
 3 score = Bayesian score of Tree computed using Equation 4 
 4 LOOP 
 5   best_Score = score 
 6   found_Best_X = False 
 7   temp_Tree = Tree 
8   FOR each leaf_Node in temp_Tree 
 9    FOR each X in  free_X 
 10     Grow temp_Tree by replacing leaf_Node with X 
 11     temp_Score = Bayesian score of temp_Tree computed using Equation 4 
 12    IF temp_Score > best_Score 
 13      found_Best_X = True 
 14      best_Score = temp_Score 
 15      best_X = X 
 16     END IF 
17    END FOR 
18   END FOR 
19   IF found_Best_X = True 
 20    Grow Tree by replacing leaf_Node with best_X  
 21    Remove best_X from free_X 
 22   ELSE 
 23    EXIT from LOOP 
 24   END IF 
 25  END LOOP 
 26  Return Tree 
  
Figure 2: Pseudocode for the SDTA 
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3.2.3 Example of SDT model 
In order to illustrate how the SDTA works, consider a training dataset D = (X, Y), consisting of 
200 individuals with two SNVs, X1 and X2, and a target variable Y (either diseased or healthy). 
Each SNV has three genotypes coded as 0, 1, and 2 (for major homozygote, heterozygote, and 
minor homozygote, respectively). Target Y can take two values 1 and 0 denoting diseased and 
healthy respectively.  Of the 200 persons, 20 have Y = 1, and 180 have Y = 0. 
Figure 3 shows an SDT model built using SDTA and the Bayesian score described in 
Section 3.2.2. The counts of healthy and diseased individuals assigned to each node are shown as 
[number of healthy, number of diseased]. This model contains only variables X1 and X2 as being 
informative for predicting Y in D. For example, the probability of being healthy or diseased in 
the bottom right leaf node, with leaf counts [2, 1], can be computed from the Bayesian estimator 
in Equation 1. Setting the prior αlk to 1, which represents a uniform prior probability distribution, 
Nlk = number of healthy = 2 
Nl = number of healthy + number of diseased = 3 
αl = 1 + 1 = 2.  
Therefore the probability of being healthy at this leaf node is (1+2)/(2+3) = 0.6. 
 
Inference. Let A be a test individual (not present in D) for whom we want to predict Y, and for 
whom the SNV features are X1 = 2, X2 = 1, X3 = 0, X4 = 2, and Y = 1. The SDTA will find the path 
with features matching those of A. In this case, they are X1 = 2, X2 = 1, which leads to the leaf 
node with counts of [4, 3]. The probability of disease for A is (1+3)/(2+3+4) = 0.44 
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Figure 3: Example SDT model 
3.3 PERSONALIZED DECISION TREE (PDT) 
This section provides a detailed description of the PDT model, and then describes the PDTA that 
uses a Bayesian approach to create patient-specific (PS) path from the SDTA. Again, the model 
searches for a tree with highest posterior probability, this time using both the dataset D and the 
single test instance from Dtest. 
3.3.1 PDT model 
The model constructed by the PDTA takes as input the features of the current person and outputs 
a probability distribution over the target variable. First, an SDT is built from D and fixed. This 
tree is used by the PDT to generate the PS path and its corresponding residual decision tree 
(RDT). The extension of the PS path is terminated if the addition of the best candidate predictor 
does not improve the score while building the model. Consequently, if there is no PS path that 
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leads to improvement of PDT over the SDT, no PS path + RDT is created, and the PDT is 
identical to the SDT. 
 
Model structure and parameters. Structurally, the PDT is comprised of two concurrent 
decision networks: One is the PS path that is personalized to the subject from Dtest, the other is 
the RDT (similar to the SDT, but with certain predictors removed when they are chosen to be 
added to the PS). All training cases are assigned to a single path in either the PS or RDT – the 
model is scored considering both as a unit model MPDT, built from D and the single instance from 
Dtest. The PDT model differs from the SDT model by having L+1 paths, with the additional PS 
path set as RL+1. 
 
Parameter estimation. The parameterization θ proceeds similar to that in SDT; the 
parameter is given by the same Equation. 1: 
 
- with the notable difference: in this case, l ranges from 1 to L+1, to account for the 
additional PS path. 
 
Inference. Given a test subject Xtest = xtest, the parameterized model M is used to compute 
the probability distribution over the target variable Ytest of the test subject. If there is a PS path, 
then parameters in the leaf node of RL+1 are returned. If there is no PS path, then inference is 
performed on the RDT by sequentially identifying the outbound branch at each interior node, 
starting at the root node, by the value of the predictor associated with the node in the test subject 
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the identify the relevant path Rtest that fits the test subject features. The parameters in the leaf 
node of Rtest are then returned. 
3.3.2 Description of PDTA 
PDTA uses a Bayesian approach similar to STDA. Below I detail the ways in which PDTA 
differs from STDA. 
3.3.2.1 Model score 
The derivation of the model score for PDTA is identical to that for SDTA. Since there are L+1 
paths to consider in a PDT, I modify Equation 4 (Section 3.2.2) to set the score of model M as: 
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3.3.2.2 Search strategy 
The PDTA fixes the tree derived by SDTA, then uses a heuristic greedy search to derive RL+1. 
All of the predictors, including the ones in the tree, are allowed to be candidates for inclusion in 
the PS path.  
The pseudocode for growing the PDT is given in Figure 4. The search begins by selecting 
a predictor Xchosen for the PS path, and assigning to it the set of individuals from D who all have 
the same value for the Xchosen as the current patient from Dtest; that set is denoted D(L+1). The 
individuals in D(L+1) are removed from the paths in full tree to which they had been originally 
assigned, leaving the remainder RDT. This process of selecting a predictor and extending the PS 
path continues. Similar to the SDT search method, the PS path is extended by adding one best 
predictor at a time, and the goodness of a candidate predictor is evaluated by temporarily adding 
it to the PS path and computing the score of MPDT. The extension of the PS path is terminated if 
the addition of the best candidate predictor does not improve the score of the current model. 
The PDTA may not find a distinct person-specific path for every person. When PDTA is 
unable to improve upon any of the paths in the SDT, it uses one of the SDT paths to predict the 
current person.  
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PDTA (X, D, Dtest) 
 Input:  X is a set of predictor variables 
     D is a training dataset of individuals described using X, a set of predictor 
      variables, and target variable Y 
     Dtest is data for individual of interest described using X 
Output: Residual_Tree + PS where PS is patient-specific path personalized with Dtest  
 
  
 1 Residual_Tree = SDTA (X, D) 
 2 PS = null 
 3 free_X = list of all predictor variables  
 4 score = Bayesian score of Residual_Tree + PS computed using Equation 12 
 5 LOOP 
 6   best_Score = score 
 7   found_Best_X = False 
 8   temp_Residual_Tree = Residual_Tree 
 9   temp_PS = null 
 10   FOR each X in free_X 
11    Grow temp_PS by replacing leaf_Node with X = value in Dtest 
12    Remove individuals from temp_Residual_Tree who are assigned to temp_PS 
13    temp_Score = Bayesian score of temp_Residual_Tree + temp_PS computed  
        using Equation 12 
 14   IF temp_Score > best_Score 
 15     found_Best_X = True 
 16     best_Score = temp_Score 
 17     best_X = X 
 18    END IF 
 19   END FOR 
 20   IF found_Best_X = True 
 21    Grow PS by replacing leaf_Node with best_X  
 22    Remove best_X from free_X 
23     Remove individuals from Residual_Tree who are assigned to PS 
 24   ELSE 
 25    EXIT from LOOP 
 26   END IF 
 27  END LOOP 
7 27  Return Residual_Tree + PS 
 
Figure 4: Pseudocode for PDTA 
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3.3.3 Example PDT model 
In order to illustrate how the PDT works, let us consider the same training dataset D from 
Section 3.2.3. Figure 5 shows the PDT model built using PDTA and the score as described in 
Section 3.3.2.1, comprised of a PS path and an RDT. As in the SDT example, the parameters in 
the leaf nodes are estimated from D using the Bayesian estimator in Equation 1.  
  The PS path, which contains the SNV X2 = 2, is applicable only to the subgroup in D 
whose members have X2 with the value 2, as does the current person. The PS path does not 
contain the predictor X1 because it did not improve the prediction for this subgroup. The residual 
tree serves as the default predictive model for those individuals in D who do not satisfy the PS 
path (i.e., for individuals whose features are not similar to the current person). The shaded leaf 
nodes in the RDT indicate leaf nodes from which individuals were removed to populate the leaf 
node of the PS path. 
 
Inference. Given test individual A, and the PS path which was built to match the features 
in A, and X1 = 0, X2 = 2, the probability of disease is (5+1) / (5+1+15+1) = 0.273, which is higher 
than the 0.008 predicted by the model in Figure 5. 
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Figure 5: Example PDT model 
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4.0  EXPERIMENTAL METHODS 
This chapter describes the datasets, the performance metrics, the gene and variant information 
and comparison algorithms. Section 4.1 describes the datasets used in the experiments. Section 
4.2 describes the performance metrics used for model evaluation. Section 4.3 describes details of 
gene and variant information used in this dissertation. Section 4.4 gives details of the comparison 
algorithms. 
4.1 DATASETS 
This section describes the datasets used to develop and evaluate the algorithm. Each of them has 
a single binary target variable per sample to indicate its case/control status. The datasets vary in 
size, complexity, variable type and biological realism, offering a multifaceted view of algorithm 
performance. Section 4.1.1 describes the Synthetic dataset (SD), which was created to emulate a 
SNV dataset, with preset causality and frequency in the generation of variables. Section 4.1.2 
describes the small biological dataset (SBD), comprised of a curated selection of SNVs and 
wildtype/mutation pairs which are biologically realistic, with lower complexity than a full 
exomic dataset. Section 4.1.3 describes the semi-synthetic dataset (SSD), which has the full 
complexity of a real genomic dataset, but the true causal variables are known. Section 4.1.4 
describes a whole exome SNV dataset containing samples marked as cases of chronic 
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pancreatitis or recurrent acute pancreatitis (WE-CP), along with creation of a reduced variable 
version (WE-CP-R) of the dataset. Section 4.1.5 describes a subset comprised of the pancreatitis 
cases only, from WE-CP, matched for presence or absence of diabetes as phenotype (WE-DB). 
This section also contains details of the creation of the reduced variable version (WE-DB-R). 
Table 1 provides an overview of all the datasets. 
 
 
Table 1: Summary of datasets 
 Dataset Number 
of 
samples 
Number 
of 
variables 
Any 
variable 
values 
missing? 
Biological? Train set 
size 
Test set 
size 
1 SD 10,000 1,000 No No 9000 1000 
2 SBD 2,201 155 Yes Yes 1761 440 
3 SSD 6,970 24,487 No Mixed 5577 1393 
4 WE-CP 2,135 246,012 Yes Yes 1708 427 
 WE-CP-R 2,135 516 Yes Yes 1708 427 
5 WE-DB 1420 245,573 Yes Yes 1137 283 
 WE-DB-R 1420 638 Yes Yes 1137 283 
 
 
4.1.1 Synthetic Dataset (SD) 
The SD consists of 1,000 SNVs and a binary disease variable that was modelled as a function of 
35 “causal” SNVs. Of the 35 SNVs, 25 of them were modeled as rare variants, with minor allele 
frequencies (MAFs) that were sampled uniformly from the range 0.0001 to 0.01 and odds ratios 
in the range 2 to 10.  The remaining 10 of the 35 SNVs were modeled as common variants, with 
MAFs in the range 0.05 to 0.50 and odds ratios in the range 1.05 to 1.50. This choice was 
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motivated by current thinking that common variants have smaller effects than rare variants. The 
remaining 965 SNVs (“noise” variants) ranged from common to rare, but they do not have an 
effect on the disease. The dataset consists of 10,000 samples of which 13.3% had disease and the 
remaining were healthy. 
4.1.2 Small Biological Dataset (SBD) 
The SBD consists of 2,201 individuals, of whom 980 are diseased (diagnosed with CP or RAP) 
and 1,221 are healthy. I pre-processed the dataset to remove some of the individuals and the non-
genetic variables. The final dataset contained 2,201 individuals and 155 genetic variables, of 
which 142 were SNVs and 13 were binary variables (classified as either wildtype or mutant). 
This dataset was curated to create a small biological dataset containing a mix of clinical variables 
that may or may not be associated with CP or RAP. 
4.1.3 Semi-Synthetic Dataset (SSD) 
The SSD is a mini-exome semi-synthetic dataset that was constructed for the Genetic Analysis 
Workshop 17 (GAW17) held in 2010 at Boston, Massachusetts63,64. The data was obtained from 
697 unrelated individuals whose exomes were sequenced in the 1000 Genomes Project and the 
genomic data consists of 24,487 autosomal SNVs that map to 3,205 genes. This is a mini-exome 
dataset since the 3,205 genes comprise a subset of all human genes. The synthetic portion of the 
dataset consisted of four quantitative risk factors that were simulated as normally distributed 
phenotypes. The genes associated with each of the risk factors were chosen from cardiovascular 
risk and inflammation pathways. 
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For evaluation of PDTA, I used one of the 4 phenotypes as target, which was influenced 
by 72 SNVs in 13 genes and no other external factors. Of the causative SNVs for the phenotype, 
38.4% are private variants – with only one individual out of 697 having the variant – and 12.8% 
SNVs are common with MAF > 0.05. The data in the first ten GAW17 replicates were pooled to 
create the SSD with 24,487 SNVs and 6,970 samples. 
4.1.4 Whole Exome Chronic Pancreatitis (WE-CP) 
The primary data set was obtained using an IBD Exome chip with 246,212 markers, collected as 
part of the NAPS2 project65. The dataset had 2135 samples, of which 1,420 patients were 
diagnosed with either CP or RAP, and 715 were controls. Since missingness is treated as a 
feature (i.e., it can be assigned to a variable as a value) in PDTA, all variants that were missing 
in the diseased cases at a statistically significant difference from controls were removed, leaving 
246,012 SNVs in the dataset used as WE-CP. 1708 samples were used to train the model and427 
samples were used to test the model. Notably, no commonly known SNPs for PRSS1 were 
present in WE-CP. 
 In order to reduce the number of unpredictive SNVs in the dataset, all SNVs were tested 
for association with the phenotype using a chi-square test, and only those with p < 10-4 were kept 
in a new dataset, WE-CP-R. WE-CP-R contained 516 SNVs, out of which 272 had MAF < 0.05. 
4.1.5 Whole Exome Pancreatitis with Diabetes (WE-DB) 
All control subjects were removed from WE-CP to create WE-DB, with 1,420 CP-positive 
patients. This dataset was divided into cases and controls based on presence of endocrine 
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insufficiency. 374 patients had diabetes and 1046 patients were controls. PDTA was applied to 
WE-DB using 1137 samples to train the model, and 283 to test predictions. 
In order to reduce the number of unpredictive SNVs in WE-DB, all SNVs were tested for 
association with the phenotype using a chi-square test, and only those with p < 10-4 (642 SNVs) 
were saved in a new dataset, WE-CP-R. After adjusting for missingness, WE-DB-R was left with 
638 SNVs, out of which 395 had MAF < 0.05. 
4.2 PERFORMANCE METRICS 
4.2.1 Area under the ROC curve (AUC) 
Receiver Operating Characteristic (ROC) curves are commonly used to evaluate the predictive 
performance of machine learning algorithms, with the area under ROC (AUC) used as a 
summary statistic of discrimination66. In brief, the ROC curve illustrates the tradeoff between 
true positive rate (also known as sensitivity) and false positive rate (incorrectly identified 
controls). An algorithm with perfect discriminability would have an AUC of 1; one that performs 
no better than chance would have an AUC of 0.5. To evaluate the predictive performance of an 
algorithm I computed the AUC from the predictions for each individual in the test set. 
Confidence intervals for the AUCs were computed using method of DeLong, using the pROC 
package in R67,68. 
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4.2.2 Minimal Split Ratio (MSR) 
In this work, I created a metric called Minimal Split Ratio (MSR), as a measurement of how 
susceptible the model may be to noise. The MSR of a tree model is based on the proportion of 
terminal leaf nodes classifying on a low count of samples versus a robust number of samples, 
with a slight smoothing function. 
4.2.3 Causal variable detection 
For the datasets in which the casual variables are known, I report positive predictive value 
(PPV), true positive rate (TPR), and the F1 score. When the algorithm predicts an instance as 
positive for a condition, a ‘true positive’ (TP) is when the instance was correctly identified as 
positive, a ‘false positive’ (FP) is when the instance was incorrectly identified as positive. 
Likewise, the prediction of an instance as negative for the condition can be either ‘true negative’ 
(TN), when the absence of the condition is correctly identified, or a ‘false negative’ (FN), when 
the presence of the condition was missed. In evaluating a predictor, the acceptable tradeoff 
between TP, FP, TN and FN depends on the priorities of the application. The PPV, also known 
as precision, gives the ratio of TP to the total number of instances predicted as positive. The 
TPR, also known as sensitivity or recall, gives the ratio of TP to the total number of instances 
that were truly positive for the condition. The F1 score is a weighted average of PPV and TPR, 
ranging in value between 0 and 1, with values closer to 1 better than values closer to 0. 
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4.3 GENE AND VARIANT INFORMATION 
4.3.1 PDTA conventions 
The PDTA is designed to consider all possible values of a variable in determining the edge, or 
branch, to be placed emerging from a node. Since I am interested in representing SNVs at the 
nodes, I categorize the possible values of the variable as: 
 0: Major homozygous, or wildtype 
 1: Heterozygous 
 2: Minor homozygous, or biallelic mutant 
 3: Missing 
Therefore, listing the paths in a tree (Figure 6) where the root node, rs123, branches to 
node rs456 when it is heterozygous (SNV=1), and to node rs789 when it is minor homozygous 
(SNV=2), would be represented by the two paths: 
rs123--[1]--rs456 
rs123--[2]—rs789 
 
 
Figure 6: Example tree with two paths, node counts and edges. 
Brackets inside the node show counts of instances at that node for the binary 
outcome (such as [healthy, disease]) 
 
In all analyses, SNV with MAF < 0.05 are referred to as rare SNVs. 
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4.3.2 Tools and Databases 
PLINK was used for association analysis, MAF calculation and manipulation of WE-CP and 
WE-DB69. NCBI dbSNP was referenced for information on all model SNVs, retrieved before 
June 2018. The global MAF I use from dbSNP are the values reported by NHLBI Trans-Omics 
for Precision Medicine (TOPMed)70. A full list of databases used for referencing genes and 
SNVs in this work is shown in Table 2. 
 
Table 2: Resources for gene and variant information 
 Web location Description 
dbSNP 71 www.ncbi.nlm.nih.gov/snp/ Database of single nucleotide polymorphisms (SNPs) and 
multiple small-scale variations that include 
insertions/deletions, microsatellites, and non-polymorphic 
variants 
ClinVar 72 www.ncbi.nlm.nih.gov/clinvar/ Public archive of relationships among genomic variation and 
human phenotype 
Pancreas Genetics 
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www.pancreasgenetics.org Database of gene variants assembled from published reports 
and personal submissions from investigators 
Pancreatic Cancer 
Database 74 
www.pancreaticcancerdatabase.org Database of manually curated molecular alterations 
associated with pancreatic cancer from research articles 
SNPedia 75 www.snpedia.com Bioinformatics wiki supporting genome annotation, 
interpretation and analysis 
4.4 COMPARISON ALGORITHMS 
4.4.1 Regular decision tree 
To compare the performance of PDTA to a regular decision tree, I used the decision tree 
classifier in Scikit-learn with default parameters76. This package uses an optimized version of the 
 46 
Classification and Regression Trees (CART) algorithm, a non-parametric learning method which 
grows a tree based on information gain at each node77. 
4.4.2 K2 Bayesian score 
To assess the choice of BDeu score in PDTA, I compare its performance to implementations of 
PDTA which instead used another Bayesian score, K278. The BDeu and K2 scores both derive 
from the Bayesian Dirichlet (BD) score; the K2 score is a specialization of the BD score which 
assumes an uninformed prior assignment. Unlike BDeu, the K2 score does not require 
specification of parameter priors. Variations of the K2 score have been used in other studies as 
uniform prior score metric (UPSM) and Dirichlet prior score metric (DPSM)79,80. 
4.4.3 Akaike Information Criterion (AIC) 
The Akaike Information Criterion (AIC) approaches scoring Bayesian networks as an 
information theoretic task: it estimates the quality of each model according to relative 
information loss when that model is used to represent the process that generated the data81. 
4.4.4 Minimum Description Length (MDL) score 
The Minimum Description Length (MDL) score also approaches scoring Bayesian networks as 
an information theoretic task82. MDL is often used interchangeably with the BIC, as they are 
equivalent under certain conditions80. In many applications, MDL has been shown to outperform 
other scores such as BDeu and AIC, but it may not work well on smaller datasets83,84. 
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5.0  EXPERIMENTAL RESULTS 
This chapter describes the results of applying the algorithms described in Chapter 3 to the 
datasets described in Chapter 4. Section 5.1 describes the iterative development of PDTA on SD. 
Section 5.2 describe the evaluation of the final developed PDTA on the rest of the datasets. 
5.1 EVALUATION AND ITERATIVE REFINEMENT OF PDTA ON SD 
In this section, I describe the algorithmic performance on a synthetic dataset, and test 
improvements to PDTA, first optimizing the initial tree building part of the algorithm (SDTA), 
followed by the instance-based personalization part of the algorithm (PS paths). The score used 
by PDTA for choosing nodes requires the setting of values for two hyperparameters: α and ENP. 
In Section 5.1.1, I present an assessment of the effect that these hyperparameter values have on 
the model. This is followed by further experiments in refining the algorithm for PDTA model 
selection (5.1.2, 5.1.3). In Section 5.1.4, I summarize my observations on SD.  
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5.1.1 Empirical Optimization of PDT on SD 
The SD is a dataset where the true causal predictors are known. Therefore, we can assess the 
performance of PDTA on SD not only for accuracy in classification (measured by AUC), but 
also for accuracy in the selection of causal variables (measured by F1, PPV and TPR). The 
PDTA score requires two hyperparameters to be set: ENP, which influences the structure prior, 
and α, which influences the BDeu score. First, SDTA was applied to the SD with the 
combination of α and ENP values as shown in Table 3. 
 
 
Table 3: Hyperparameter settings used in SDTA on SD 
 
 
The trend of SDTA performance with these settings is shown in terms of AUC (Figure 
7a) and F1 score (Figure 7b). In general, a higher F1 score indicates the model is better at 
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retrieving the true causal variables as predictive variables (nodes in the tree), while minimizing 
false negatives. It is important to note that there are only 35 causal variables in the SD, so the F1 
score for large trees which have more than 35 nodes will automatically suffer from a lower PPV. 
An additional metric, which I call MSR (Figure 7c), is a measurement of how susceptible the 
model may be to noise, based on the proportion of leaves classifying on a low count of samples 
versus a robust number of samples. Lower values of ENP produce SDTs with better AUC, F1 
and MSR across all values of α. 
 
 
Table 4: 10 best SDTs on SD, ranked by lowest MSR 
 
Model MSR AUC 95% CI  α ENP # of  
leaves 
# of  
nodes 
# of 
causal 
SNVs 
PPV TPR  F1 
SDT1 0.431 0.987 0.982-0.992 50 1 49 24 24 1.000 0.686 0.814 
SDT2 0.449 0.987 0.982-0.992 10 1 47 23 23 1.000 0.657 0.79 
SDT3 0.449 0.987 0.982-0.992 1 1 47 23 23 1.000 0.657 0.79 
SDT4 0.479 0.986 0.980-0.992 50 5 71 35 28 0.800 0.800 0.80 
SDT5 0.489 0.983 0.974-0.993 0.001 1 43 21 20 0.952 0.571 0.71 
SDT6 0.490 0.983 0.974-0.993 0.005 1 47 23 22 0.957 0.629 0.76 
SDT7 0.490 0.983 0.974-0.993 0.01 1 47 23 22 0.957 0.629 0.76 
SDT8 0.490 0.986 0.980-0.992 0.05 1 49 24 23 0.958 0.657 0.78 
SDT9 0.490 0.986 0.980-0.992 0.1 1 49 24 23 0.958 0.657 0.78 
SDT10 0.490 0.986 0.980-0.992 0.5 1 49 24 23 0.958 0.657 0.78 
 
 
Higher values of ENP and α tend to grow larger trees (Figure 8a). The number of nodes 
in a tree increases monotonically with increase in the value of ENP (Figure 8b), but not with 
increase in the value of α (Figure 8c). Lower MSR values are seen with smaller tree sizes (Figure 
8d), and many of these also have the highest AUC values (Figure 8e). The tree with the lowest 
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MSR value, SDT1 in Table 4 (AUC = 0.987, 95% C.I.: 0.982-0.992, F1 = 0.814) performed 
almost as well as the tree with overall highest AUC value (AUC = 0.989, 95% C.I.: 0.985-0.994, 
F1 = 0.889), which was produced with parameters α = 1000, ENP = 1. 
As can be seen in Figures 1 and 2, trees with lower MSR values tend to have better 
performance as measured by both AUC and F1, and lower ENP values are sufficient to generate 
high scoring SDTs across all measures of performance. From these observations, I hypothesize 
that larger SDTs, with higher ENP values – which take much longer to build – may be a poor use 
of resources, and we can select the best SDT by choosing the model with the lowest MSR value. 
Therefore, the α and ENP values for lowest MSR SDT, SDT1, are applied to test PDTA on the 
SD. The best ENP value observed for SDT was retained as tree ENP, and a range of path ENPs 
were used to test for PS path creation (Table 5). 
 
 
Table 5: Results of PDTA on SD with best SDT parameters  
(SDT1 in Table 4) 
 
Model α Tree 
ENP 
Path 
ENP 
# of times PS 
chosen (out of 
1000) 
SDT 
AUC 
95% CI PDT 
AUC 
95% CI 
PDT1 50 1 1 0 0.987 0.982-0.992 0.987 0.982-0.992 
PDT2 50 1 20 12 0.987 0.982-0.992 0.986 0.981-0.992 
PDT3 50 1 50 12 0.987 0.982-0.992 0.986 0.981-0.992 
PDT4 50 1 100 12 0.987 0.982-0.992 0.986 0.981-0.992 
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Figure 7: Trend of SDTA on SD 
(a) AUC, (b) F1, (c) MSR 
(a) 
(b) 
(c) 
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Figure 8: Trend of SDTA on SD, continued 
(a) Size of trees trend by both hyperparameters; (b) Size of trees grow monotonically with ENP, 
(c) Size of trees grow with Alpha, but not monotonically, (d) & (e) Smaller trees have lower 
MSR but still high AUCs. 
(b) 
(d) 
(c) 
(e) 
(a) 
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As seen in Table 5, in PDT1 (the lowest attempted path ENP), no PS paths were selected. That 
means that all patients in the test dataset matched best to a path in the SDT. In PDT2, however, 
12 out of the 1000 test instances were assigned to PS paths, but there was no improvement in 
AUC. Increasing the path ENP (PDT3, PDT4) neither recruited additional PS paths to the model, 
nor improved AUC. Therefore, the best model generated for SD by PDTA is SDT1 from Table 
4. The frequency of paths in SDT1 chosen by test instances is shown in Table 6. All SNVs 
chosen as internal nodes in the SDT are causal variables, and most of the nodes chosen per path 
are rare causal variables (Table 6). 
When PS paths were selected by test instances, there were 3 unique paths, 2 of which 
included rare causal variables. PDT2 (Figure 9a) had the lowest path ENP value where PS paths 
were created. As path ENP increased, PS paths were created again in PDT3and PDT4, but they 
differed from the paths in PDT2 only in the addition of a single SNV, v372 (Figure 9b). This 
SNV, v372, was one of the noise variants in SD, not a causal variant. Recall the earlier 
observation that higher tree ENPs tend to generate larger SDTs without a corresponding 
improvement in performance (Figure 8a); it appears, similarly, that higher path ENPs will add 
more nodes to the PDT, even without adding value to the model. 
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Table 6: Paths selected from SDT1 by SD test instances, ranked by frequency 
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SDT_Path1 v24--[0]--…--v30--[0] 514 [1.0,0.0] [514,0] 19 [4781,5] 19 18 
SDT_Path2 v24--[0]--…--v27--[0] 204 [1.0,0.0] [204,0] 22 [1773,7] 22 20 
SDT_Path3 v24--[0]--…--v27--[1] 58 [0.96,0.04] [58,0] 22 [357,13] 22 20 
SDT_Path4 v24--[0]--…--v30--[2] 32 [0.98,0.02] [32,0] 19 [258,4] 19 18 
SDT_Path5 v24--[0]--…--v2--[1] 27 [0.1,0.9] [1,26] 2 [16,148] 2 2 
SDT_Path6 v24--[0]--…--v17--[1] 14 [0.03,0.97] [0,14] 3 [3,111] 3 3 
SDT_Path7 v24--[0]--…--v22--[1] 12 [0.22,0.78] [4,8] 5 [24,84] 5 5 
SDT_Path8 v24--[0]--…--v4--[1] 12 [0.48,0.52] [4,8] 9 [61,66] 9 9 
SDT_Path9 v24--[0]--…--v14--[1] 11 [0.47,0.53] [6,5] 10 [46,53] 10 10 
SDT_Path10 v24--[0]--…--v8--[1] 11 [0.26,0.74] [3,8] 6 [29,85] 6 6 
SDT_Path11 v24--[0]--…--v12--[1] 11 [0.49,0.51] [5,6] 8 [75,77] 8 8 
SDT_Path12 v24--[0]--…--v9--[1] 10 [0.71,0.29] [5,5] 15 [63,26] 15 15 
SDT_Path13 v24--[0]--…--v5--[1] 10 [0.54,0.46] [3,7] 11 [63,54] 11 11 
SDT_Path14 v24--[0]--…--v13--[1] 8 [0.79,0.21] [6,2] 16 [79,21] 16 16 
SDT_Path15 v24--[0]--…--v10--[1] 8 [0.04,0.96] [0,8] 4 [4,96] 4 4 
SDT_Path16 v24--[0]--…--v7--[1] 8 [0.79,0.21] [5,3] 17 [51,13] 17 17 
SDT_Path17 v24--[1]--…--v26--[0] 7 [0.17,0.83] [0,7] 2 [13,64] 2 1 
SDT_Path18 v24--[0]--…--v19--[1] 6 [0.05,0.95] [1,5] 12 [1,27] 12 12 
SDT_Path19 v24--[0]--…--v23--[1] 5 [0.81,0.19] [4,1] 21 [31,7] 21 20 
SDT_Path20 v24--[0]--…--v27--[2] 5 [0.94,0.06] [5,0] 22 [23,1] 22 20 
SDT_Path21 v24--[0]--…--v11--[1] 5 [0.18,0.82] [2,3] 13 [5,24] 13 13 
SDT_Path22 v24--[0]--…--v1--[1] 5 [0.22,0.78] [4,1] 14 [6,22] 14 14 
SDT_Path23 v24--[1]--…--v26--[1] 4 [0.01,0.99] [0,4] 2 [0,74] 2 1 
SDT_Path24 v24--[0]--…--v25--[1] 3 [0.02,0.98] [0,3] 8 [0,32] 8 7 
SDT_Path25 v24--[0]--…--v25--[2] 2 [0.1,0.9] [0,2] 8 [0,4] 8 7 
SDT_Path26 v24--[1]--…--v26--[2] 2 [0.02,0.98] [0,2] 2 [0,26] 2 1 
SDT_Path27 v24--[0]--…--v6--[1] 2 [0.59,0.41] [2,0] 20 [9,6] 20 19 
SDT_Path28 v24--[0]--…--v0--[1] 2 [0.69,0.31] [2,0] 18 [21,9] 18 18 
SDT_Path29 v24--[0]--…--v14--[2] 1 [0.5,0.5] [0,1] 10 [0,0] 10 10 
SDT_Path30 v24--[0]--…--v25--[0] 1 [0.42,0.58] [0,1] 8 [19,26] 8 7 
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Figure 9: PS paths generated by PDTA  
(a) in PDT2, Table 5, (b) in PDT3 and PDT4, Table 5 
 
5.1.2 Refinements to improve generalization 
The PDTA only builds trees by growing them, as the BDeu score is expected to control well for 
overfitting49. However, it could be worthwhile to check if the tree can be improved by taking 
measures to reduce overfitting at the leaves. There are two common ways to accomplish this: one 
is by incorporating a termination rule in the tree growth phase, such that the tree stops adding 
nodes when it has reached a minimum number of sample counts; another is by adding a tree 
(b) 
(a) 
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pruning phase after the tree growth phase. Both of these methods were tried on SDTA with the 
following results. 
When a termination rule was added to the SDTA, the effect of parameter settings (Figure 
10, 11) are qualitatively different from the original SDTA (Figure 7). There are a few similarities 
in trends: trees with lower MSR values (Figure 10c) show better performance by both AUC 
(Figure 10a) and F1 (Figure 10b), higher values of ENP and α tend to grow larger trees (Figure 
11a), and the growth in number of nodes in a tree increases monotonically with value of ENP 
(Figure 11b), but not with value of α (Figure 11c). Compared to the original SDTA, however, the 
resulting trees were much smaller (Figure 11a), and performed significantly worse (Figure 10a, 
11a). Smaller trees tend to have better MSR values (Figure 11d), and SDTs with lower MSR 
values have higher AUCs (Figure 11e), so the choice of best model by lowest MSR value is still 
sound. Table 7 shows details on the 10 best trees, ranked by the lowest MSR values. The tree 
with lowest MSR value, SDT1 in Table 7 (AUC = 0.677, 95% CI: 0.623-0.732; F1 = 0.2) 
performed only slightly less well than the tree with overall highest AUC value (AUC = 0.689, 
95% CI: 0.637-0.742; F1 = 0.34), which resulted from parameters α = 50, ENP = 15. These 
results show that adding a termination rule to the tree-building phase diminishes the performance 
of SDTA. 
 57 
 
 
 
 
 
 
 
 
 
Figure 10: Trend of SDTA on SD with termination rule 
(a) AUC, (b) F1, (c) MSR 
(b) 
(c) 
(a) 
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Figure 11: Trend of SDTA on SD with termination rule, continued 
(a) Size of trees trend by both hyperparameters, (b) Size of trees grow monotonically 
with ENP, (c) Size of trees grow with Alpha, but not monotonically, (d) & (e) Smaller trees have 
lower MSR but still high AUCs 
(b) (c) 
(a) 
(d) (e) 
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Instead of adding a termination rule, the other method of reducing overfit was 
implemented by allowing SDTA to grow a full tree based solely on the best score, with a tree 
pruning phase added after the growth phase. As seen in Figures 12 and 13, the trends of 
parameter settings on performance metrics are almost identical to the trends seen for the original 
SDTA (Figures 7 and 8). The best performing models (Table 8) also look similar to the results 
obtained before pruning was applied (Table 4), and the best performing tree SDT1 in Table 8 
(AUC = 0.987, 95% CI: 0.982-0.992); F1 = 0.814) performed just as well as SDT1 in Table 4. 
 
Based on these observations, I concluded that: 
(1) The addition of a termination rule to the tree building phase of the algorithm is 
detrimental to PDTA. 
(2) The addition of pruning following the tree building phase of the algorithm is not 
detrimental to PDTA. 
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Table 7: 10 best SDTs on SD with termination rule, ranked by lowest MSR 
 
Model MSR AUC 95% CI     α ENP # of 
leaves 
# of 
nodes 
# of 
causal 
SNVs 
PPV TPR F1 
SDT1 0.231 0.677 0.623-0.732 10 25 11 5 4 0.800 0.114 0.200 
SDT2 0.231 0.677 0.623-0.732 10 30 11 5 4 0.800 0.114 0.200 
SDT3 0.267 0.671 0.616-0.726 1 100 13 6 4 0.667 0.114 0.195 
SDT4 0.273 0.680 0.624-0.736 10 10 9 4 4 1.000 0.114 0.205 
SDT5 0.273 0.680 0.624-0.736 10 15 9 4 4 1.000 0.114 0.205 
SDT6 0.273 0.680 0.624-0.736 10 1 9 4 4 1.000 0.114 0.205 
SDT7 0.273 0.680 0.624-0.736 10 20 9 4 4 1.000 0.114 0.205 
SDT8 0.273 0.680 0.624-0.736 10 5 9 4 4 1.000 0.114 0.205 
SDT9 0.273 0.680 0.624-0.736 1 25 9 4 4 1.000 0.114 0.205 
SDT10 0.273 0.680 0.624-0.736 1 30 9 4 4 1.000 0.114 0.205 
 
 
Table 8: 10 best SDTs on SD with pruning, ranked by lowest MSR 
 
Model MSR AUC 95% CI  α ENP # of    
leaves 
# of   
nodes 
# of 
causal 
SNVs 
PPV TPR F1 
SDT1 0.431 0.987 0.982-0.992 50 1 49 24 24 1.000 0.686 0.814 
SDT2 0.449 0.987 0.982-0.992 10 1 47 23 23 1.000 0.657 0.793 
SDT3 0.468 0.987 0.982-0.992 1 1 45 22 22 1.000 0.629 0.772 
SDT4 0.469 0.986 0.980-0.992 0.5 1 47 23 23 1.000 0.657 0.793 
SDT5 0.475 0.986 0.981-0.992 10 5 59 29 28 0.966 0.800 0.875 
SDT6 0.479 0.986 0.980-0.992 50 5 69 34 28 0.824 0.800 0.812 
SDT7 0.492 0.989 0.984-0.994 500 1 57 28 28 1.000 0.800 0.889 
SDT8 0.507 0.989 0.984-0.994 1000 5 73 36 28 0.778 0.800 0.789 
SDT9 0.507 0.989 0.984-0.994 500 5 65 32 28 0.875 0.800 0.836 
SDT10 0.508 0.988 0.983-0.993 100 5 63 31 28 0.903 0.800 0.848 
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Figure 12: Trend of SDTA on SD with pruning  
(a) AUC, (b) F1, (c) MSR 
(b) 
(a) 
(c) 
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Figure 13: Trend of SDTA on SD with pruning, continued 
(a) Size of trees trend by both hyperparameters; (b) Size of trees grow monotonically with ENP; 
(c) Size of trees grow with Alpha, but not monotonically; (d) & (e) Smaller trees have lower 
MSR but still high AUCs 
(b) 
(a) 
(d) 
(c) 
(e) 
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5.1.3 Refinements for genetic models 
The current implementation of PDTA assumes a genotype model where each of three genotypes 
at an SNV is treated as an independent value. However, in genetic studies, it is common to test 
using genotype classes, such as dominant or recessive models 85. Consider the typical case where 
the possible alleles at a locus are A (wildtype) and a (variant). A dominant genetic model 
assumes that having one or more copies of the a allele will result in disease. A recessive genetic 
model assumes that two copies of the a allele must be present to result in disease. In order to 
allow for such effects, PDTA was implemented to calculate the score using not only independent 
values for each variable, but also combinations of variable values, i.e., the branch emerging from 
a node can take one or more values. 
When this feature was added to the SDTA, the effect of parameter settings exhibited 
trends similar to the original SDTA in Figure 7: trees with lower MSR values (Figure 14c) still 
had better performance by both AUC (Figure 14a) and F1 (Figure 14b). The one notable 
difference was an increase in size of many of the trees; more nodes were being recruited to the 
trees for the same hyperparameters, compared to results seen in Figure 7 (Table 9). 
I conclude that adding the genotype adaptation to PDTA does not reduce the performance 
of PDTA. 
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Figure 14: Trend of SDTA on SD with pruning and genotype adaptation 
(a) AUC, (b) F1, (c) MSR 
(b) 
(a) 
(c) 
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Figure 15: Trend of SDTA on SD with pruning and genotype adaptation, continued 
(a) Size of trees trend by both hyperparameters, (b) Size of trees grow monotonically with ENP, 
(c) Size of trees grow with Alpha, but not monotonically, (d) & (e) Smaller trees have lower 
MSR but still high AUCs 
(b) 
(a) 
(d) 
(c) 
(e) 
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Table 9: 10 best SDTs on SD with pruning and genotype adaptation, ranked by lowest MSR 
 
Model MSR AUC 95% CI 
(Delong) 
α ENP # of    
leaves 
# of     
nodes 
# of 
causal 
SNVs 
PPV TPR F1 
SDT1 0.071 0.987 0.982-0.992 0.5 1 26 25 23 0.920 0.657 0.767 
SDT2 0.071 0.987 0.982-0.992 1 1 26 25 23 0.920 0.657 0.767 
SDT3 0.103 0.987 0.982-0.992 0.01 1 27 26 23 0.885 0.657 0.754 
SDT4 0.103 0.987 0.982-0.992 0.05 1 27 26 23 0.885 0.657 0.754 
SDT5 0.103 0.987 0.982-0.992 0.1 1 27 26 23 0.885 0.657 0.754 
SDT6 0.107 0.987 0.982-0.993 0.005 1 26 25 22 0.880 0.629 0.733 
SDT7 0.111 0.986 0.980-0.992 0.001 1 25 24 21 0.875 0.600 0.712 
SDT8 0.182 0.987 0.982-0.993 10 1 31 26 24 0.923 0.686 0.787 
SDT9 0.214 0.987 0.982-0.993 10 5 40 35 27 0.771 0.771 0.771 
SDT10 0.231 0.976 0.961-0.991 0.001 5 37 35 22 0.629 0.629 0.629 
 
 
Table 10: Results of PDTA on SD with pruning and genotype  
with best SDT building parameters (SDT1 in Table 9) 
 
α 
Tree 
ENP 
Path 
ENP 
# times PS 
chosen (out of 
1000) 
SDT 
AUC 95% CI 
PDT 
AUC 95% CI 
0.5 1 1 0 0.987 0.982-0.992 0.987 0.982-0.992 
0.5 1 20 0 0.987 0.982-0.992 0.987 0.982-0.992 
0.5 1 50 0 0.987 0.982-0.992 0.987 0.982-0.992 
0.5 1 100 6 0.987 0.982-0.992 0.987 0.982-0.992 
 
5.1.4 Conclusions 
The PDTA performed very well, with AUC = 0.98, on the SD dataset, and uncovers rare 
variables as predictors in patient subgroups. Based on further tests, the PDTA was updated with 
two features: the genotype adaptation during the tree building phase, and the pruning step after 
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the tree building phase. The AUC performance of the original PDTA on SD was already close to 
0.99 so there was not much room for improvement. These additions have pragmatic value to the 
interpretability of the model, which is important for my purpose of patient-specific 
subgroupings; so since they did not reduce the performance on SD when added to PDTA, they 
were added as the final version of PDTA for all future tests of this algorithm. 
Unlike some of the observations in the literature, increasing values of α did not lead to a 
monotonic increase in edges recruited to the tree56. This underscores the importance of empirical 
testing of the algorithm for score behavior. 
5.2 EVALUATION OF PDTA 
In section 5.1, I presented the evaluation and iterative refinement of the algorithm on a synthetic 
dataset. Although SD was designed as a realistic dataset, real genomic datasets are likely to have 
noise and mixtures of distributions that are more difficult to discover. Therefore, it is important 
to evaluate the performance of PDTA on real genomic datasets. However, we do not know all of 
the true causal variables in real datasets, so we cannot assess the algorithm for true positives in 
the straightforward way we could with SD.  
In this section, I present results from the refined version of PDTA on several different 
datasets, each of which has different properties, and is informative in different ways on PDTA 
performance. In section 5.2.1, I use SBD, which is curated from a real genomic dataset, while 
having lower dimensionality than genomic datasets. In section 5.2.2 I use SSD, which represents 
the full complexity of a real genomic dataset, with synthetic causal variables; nevertheless, the 
true causal variables are available for evaluating algorithmic performance. In section 5.2.3 I use 
 68 
CP-WE, which is a whole exome dataset. In section 5.2.4 I use CP-DB, which has a smaller 
number of samples than CP-WE, but has the same dimensionality as CP-WE. 
5.2.1 Evaluation of refined PDTA on SBD 
5.2.1.1 Empirical Optimization of PDT on SBD 
To evaluate the performance of PDTA on SBD, first a search for the best SDT is performed over 
the same settings as explored in Section 5.1.1 (Table 11). 
 
 
Table 11: Hyperparameter settings used in SDTA on SBD 
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There are some similarities in the trends seen on SBD, when compared to the previous 
observations on SD (Section 5.1), and some differences. The highest AUC values are achieved 
with low ENP and high α (Figure 16a), while the best MSR value is achieved with low ENP and 
low α values (Figure 16b). It is therefore more difficult, than in the case of SD, to assess a clear 
overlap between the zone of high AUC and low MSR (Figure 16d). MSR values rise with 
increasing tree size (Figure 16c), and the lowest MSR value on SBD does not achieve the highest 
AUC (Figure 16d, Table 12), although the confidence intervals for the SDT with the highest 
AUC and the SDT with best MSR overlap. A perusal of the top ten SDTs ranked by lowest MSR 
(Table 12) and the top ten SDTs ranked by highest AUC (Table 13) shows that SDTs with lower 
MSR were much smaller (Table 12: mean number of nodes = 7.2 ± 0.42) than SDTs with higher 
AUCs (Table 13: mean number of nodes = 60.3 ± 48.94). 
Higher values of ENP and α tend to produce larger SDTs (Figure 17 a, b, c), and, 
consistent with SD observations (Section 5.1), SDTA on SBD also shows a monotonic increase 
in tree size with increasing value of ENP (Figure 17b), but not α (Figure 17 c). In fact, at ENP = 
100, the tree included all 155 variables in the SBD as nodes (Figure 17b), regardless of α value. 
Holding ENP steady at 100, the α values do not affect AUC or MSR monotonically (Figure 17 d, 
e). 
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Figure 16: Trend of SDTA performance on SBD 
(a) AUC, (b) MSR, (c) MSR increases with size of trees, (d) In a departure from trend seen with 
SD, lower MSRs are not among the highest AUCs 
(c) (d) 
(b) 
(a) 
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Figure 17: Trend of SDTA performance on SBD, continued 
(a) Size of trees trend by both hyperparameters, (b) Size of trees grow monotonically with ENP, 
(c) Size of trees grow with α, but not monotonically, (d) & (e) Influence of α on MSR and AUC 
when ENP = 100 
(e) 
(b) (c) 
(d) 
(a) 
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Table 12: 10 best SDTs on SBD, when ranked by lowest MSR 
 
 
Model MSR AUC 95% CI  α ENP # of     
leaves 
# of     
nodes 
SDT1 0.308 0.842 0.810-0.874 1 10 11 8 
SDT2 0.308 0.842 0.810-0.874 1 5 11 8 
SDT3 0.364 0.836 0.804-0.869 0.5 10 9 7 
SDT4 0.364 0.836 0.804-0.869 0.5 15 9 7 
SDT5 0.364 0.836 0.804-0.869 0.5 1 9 7 
SDT6 0.364 0.836 0.804-0.869 0.5 5 9 7 
SDT7 0.364 0.836 0.804-0.868 0.01 15 9 7 
SDT8 0.364 0.836 0.804-0.868 0.01 20 9 7 
SDT9 0.364 0.836 0.804-0.868 0.05 10 9 7 
SDT10 0.364 0.836 0.804-0.868 0.05 15 9 7 
 
 
 
Table 13: 10 best SDTs on SBD, when ranked by highest AUC 
 
Model AUC 95% CI  MSR α ENP # of    
leaves 
# of    
nodes 
SDT1 0.851 0.8155-0.8868 0.731 1000 10 65 25 
SDT2 0.851 0.8153-0.8862 0.788 1000 15 78 30 
SDT3 0.849 0.8137-0.8834 0.594 0.5 45 30 27 
SDT4 0.847 0.8114-0.8817  0.658 0.5 50 36 33 
SDT5 0.845 0.8095-0.8815 0.838 1000 20 97 38 
SDT6 0.842 0.8069-0.8779 0.500 50 1 10 4 
SDT7 0.842 0.8066-0.8776 0.921 5000 30 149 54 
SDT8 0.842 0.8099-0.8735 0.308 1 10 11 8 
SDT9 0.842 0.8099-0.8735 0.308 1 5 11 8 
SDT10 0.841 0.806-0.8768 0.839 10 35 116 68 
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5.2.1.2 Model Assessment on SBD 
The SDTs generated for different hyperparameter values do not show a clear overlap between the 
zone of high AUC and low MSR. This calls into question the assumption that the best 
performing models can be selected by low MSR. Therefore, I examine the results from running a 
full PDTA with the parameters which led to the SDT with lowest MSR (SDT1 and SDT2 from 
Table 12), followed by results from a full PDTA with parameters which led to the SDT with the 
highest AUC (SDT1 from Table 13). 
SDT1 and SDT2 from Table 12 are the best tree models as measured by MSR. These two 
models are identical, achieved by using parameter values α = 1 and tree ENP = 5, 10. The 
parameter values of SDT2 are applied to test PDTA on SBD (Table 14). None of the paths in the 
SDT contained rare SNVs. As the value of path ENP increases, the number of PS paths selected 
increases, without much corresponding improvement in PDT AUC. In PDT3 in Table 14, a 
single PS path was selected 3 times, but it did not contain any rare variables. In PDT4, two PS 
paths were selected 4 times, and one of them contained 1 rare variable. For the highest path ENP 
values, in PDT5 and PDT6, each of the PS paths were comprised of all 155 variables in the SBD. 
Despite the inclusion of all variables for patient specific signatures, PDTA did not significantly 
improve performance over the model that was obtained from SDTA. 
SDT1 from Table 13 is the best SDT measured by AUC. Its parameter values, α = 1000 
and tree ENP = 10, are applied to test PDTA on SBD (Table 15). In keeping with earlier 
observations of ENP behavior, as the path ENP is increased, more variables are included in PS 
paths. Several of the SDT paths had rare SNVs as nodes. At the highest path ENP values, PDT5 
and PDT6, each of the PS paths contained all 155 variables in the SBD. In PDT4, 7 unique PS 
 74 
paths, comprised of 2-3 nodes each, were selected 12 times. None of the PS paths contained any 
rare variables. 
 
 
Table 14: Results of PDTA on SBD with best SDT parameters by MSR 
(SDT2 of Table 12) 
 
Model α Tree 
ENP 
Path 
ENP 
# times PS 
chosen (out 
of 440) 
SDT 
AUC 
95% CI PDT 
AUC 
95% CI 
PDT1 1 5 1 0 0.842 0.810-0.874 0.842 0.810-0.874 
PDT2 1 5 20 0 0.842 0.810-0.874 0.842 0.810-0.874 
PDT3 1 5 50 3 0.842 0.810-0.874 0.842 0.810-0.873 
PDT4 1 5 70 4 0.842 0.810-0.874 0.843 0.812-0.875 
PDT5 1 5 80 7 0.842 0.810-0.874 0.843 0.812-0.875 
PDT6 1 5 100 13 0.842 0.810-0.874 0.843 0.812-0.875 
 
 
 
Table 15: Results of PDTA on SBD with best SDT parameters by AUC  
(SDT1, Table 13) 
 
Model α Tree 
ENP 
Path 
ENP 
# times PS 
chosen (out 
of 440) 
SDT 
AUC 
95% CI PDT 
AUC 
95% CI 
PDT1 1000 10 1 0 0.851 0.816-0.887 0.851 0.816-0.887 
PDT2 1000 10 20 0 0.851 0.816-0.887 0.851 0.816-0.887 
PDT3 1000 10 50 3 0.851 0.816-0.887 0.849 0.813-0.885 
PDT4 1000 10 70 12 0.851 0.816-0.887 0.849 0.813-0.885 
PDT5 1000 10 80 14 0.851 0.816-0.887 0.847 0.811-0.883 
PDT6 1000 10 100 29 0.851 0.816-0.887 0.840 0.804-0.877 
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5.2.1.3 Summary of PDTA performance on SBD 
A tree comprised of all variables could be useful as a detailed representation of individual patient 
signatures, but to gauge the ability of the algorithm to predict patient subgroups with a tractable 
set of distinct predictive variables, I prefer models that can attain high AUC with lower ENP, 
uncovering smaller sets of variables predictive of a patient subset. A model with high AUC that 
includes all available predictors in the paths would be the least useful. Given two models with 
AUCs that are similar, the smaller one (if it has a robust number of paths) would be preferable to 
the larger one.  
The observations of PDTA performance on SBD cast doubt upon my earlier assumption 
(in Section 5.1) that MSR is a good criterion for selecting the best model. When the best PDTA 
was parameterized according to best MSR, there were no rare variants in the SDT, and only a 
single rare variant found in one of the PS paths. When the best PDTA was parameterized 
according to best AUC, there were many rare variants among the paths in the SDT. Prioritizing 
MSR may be biasing the algorithm towards population-based prediction, away from individual-
based prediction. This implies that it may be better not to prioritize MSR in selection of the best 
tree, and with incorporation of pruning after the tree growth phase, concerns regarding 
overfitting are reduced.  
5.2.2 Evaluation of refined algorithm on SSD 
5.2.2.1 Empirical Optimization of PDT on SSD 
To evaluate the performance of PDTA on SSD, first a search for the best SDT is performed. The 
causal variables in the SSD dataset are known; therefore, the predictive performance of the 
models generated can be assessed not only for accuracy in classification, but also for accuracy in 
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the selection of causal variables (measured by F1, PPV and TPR). Due to the large number of 
variables in the SSD, the computational runtime of PDTA is substantially longer. In sections 
5.1.1 and 5.2.1, the results on two datasets indicated that the number of nodes in the SDT rose 
monotonically with ENP, and that the use of higher ENP may not be necessary to obtain the best 
performing tree models. Therefore, a smaller selection of ENP values was chosen to evaluate 
settings for SDTA to apply to SSD (Table 16). 
 
Table 16: Hyperparameter settings used in SDTA on SSD 
 
 
If MSR is a good criterion to use, we would need to select models with low MSR and 
high AUC. However, PDTA on SSD showed very little overlap between favorable values of 
AUC and MSR (Figure 18 a & c). Higher α and higher ENP values generated trees with better 
AUCs and worse MSR, and favoring either one over the other misses the zone of best F1 (Figure 
18 b). None of the higher ENP values generated trees with F1 greater than 0.1 (Figure 18b), and 
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higher ENP values lead to larger trees (Figure 19a & b) without corresponding improvement in 
the number of causal SNVs included in the model (Table 17). 
 
 
Table 17: 10 best SDTs on SSD, when ranked by highest AUC 
Model SDT 
AUC 
95% CI 
(Delong) 
MSR α ENP # of 
leaves 
# of 
nodes 
# of 
causal 
SNVs 
PPV TPR F1 
SDT1 0.602 0.573-0.632 0.331 1000 5000 119 73 2 0.027 0.028 0.028 
SDT2 0.602 0.573-0.631 0.293 1000 1000 73 43 2 0.047 0.028 0.035 
SDT3 0.598 0.569-0.628 0.338 1000 10000 158 102 2 0.020 0.028 0.023 
SDT4 0.595 0.566-0.624 0.241 1000 50 27 15 2 0.133 0.028 0.046 
SDT5 0.590 0.561-0.620 0.065 50 1000 43 37 3 0.081 0.042 0.055 
SDT6 0.589 0.560-0.619 0.065 50 10000 75 68 4 0.059 0.055 0.057 
SDT7 0.587 0.558-0.616 0.208 1000 20 22 12 2 0.167 0.028 0.048 
SDT8 0.585 0.556-0.615 0.077 50 5000 63 56 4 0.071 0.056 0.063 
SDT9 0.579 0.551-0.608 0.130 50 50 21 16 3 0.188 0.042 0.068 
SDT10 0.576 0.548-0.604 0.167 100 1 10 6 2 0.333 0.028 0.051 
 
 
In section 5.2.1, I made the case for choosing the best model by prioritizing high AUC 
with smaller SDT size. Looking at the SDTs that achieve best 10 AUC values (Table 17), the 
smallest is SDT10, which has 6 nodes and parameter settings α = 100, ENP = 1. This model 
successfully found 2 of the causal variables in the SSD in its SDT paths. In order to find one 
more causal variable, the minimum tree size in Table 17 increased to 16 (SDT9) and 37 (SDT5). 
SDT5 has a higher AUC, so it was selected as the more desirable model, and its parameter values 
applied to run PDTA on SSD. However, no PS paths were selected, so SDT5 remained the best 
model. 
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Figure 18: Trend of SDTA on SSD  
(a) AUC, (b) F1, (c) MSR 
(c) 
(b) 
(a) 
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Figure 19: Trend of SDTA on SSD, continued 
(a) Size of trees trend by both hyperparameters, (b) Size of trees grow monotonically with ENP, 
(c) Size of trees grow with α, but not monotonically 
(b) 
(a) 
(c) 
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Table 18: SDT paths selected by test samples of SSD, ranked by frequency 
(SDT5 of Table 17) 
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SDT_Path1 C6S5380—[0]--…—C6S458—[0, 1] 483 [0.58,0.42] 19 [1163,854] 3 14 
SDT_Path2 C6S5380—[1]--…—C17S4431—[0] 264 [0.52,0.48] 7 [541,505] 1 3 
SDT_Path3 C6S5380—[0]--…—C19S4493—[0, 2] 83 [0.67,0.33] 18 [225,112] 3 13 
SDT_Path4 C6S5380—[0]--…—C20S2249—[0] 79 [0.37,0.63] 10 [123,208] 2 4 
SDT_Path5 C6S5380—[0]--…—C1S5270—[2] 59 [0.61,0.39] 6 [154,97] 2 3 
SDT_Path6 C6S5380—[2]--…—C12S689—[1, 2] 34 [0.4,0.6] 3 [42,64] 1 0 
SDT_Path7 C6S5380—[0]--…--C9S3563—[1] 27 [0.47,0.53] 2 [48,55] 1 1 
SDT_Path8 C6S5380—[1]--…—C12S741—[2] 23 [0.29,0.71] 5 [28,69] 1 2 
SDT_Path9 C6S5380—[0]--…—C20S1784—[2] 22 [0.63,0.37] 8 [49,29] 2 3 
SDT_Path10 C6S5380—[0]--…—C13S1994—[0] 21 [0.59,0.41] 7 [53,36] 2 3 
SDT_Path11 C6S5380—[2]--…—C12S689—[0] 21 [0.16,0.84] 3 [15,84] 1 0 
SDT_Path12 C6S5380—[0]--…—C13S1994—[2] 20 [0.21,0.79] 7 [10,40] 2 3 
SDT_Path13 C6S5380—[0]--…—C6S764—[0] 20 [0.43,0.57] 4 [47,63] 2 2 
SDT_Path14 C6S5380—[1]--…—C17S2836—[0] 20 [0.13,0.87] 3 [10,70] 1 1 
SDT_Path15 C6S5380—[1]--…—C19S3805—[2] 17 [0.17,0.83] 3 [7,36] 1 1 
SDT_Path16 C6S5380—[1]--…—C17S2836—[1, 2] 15 [0.43,0.57] 3 [32,43] 1 1 
SDT_Path17 C6S5380—[0]--…—C6S458—[2] 14 [0.82,0.18] 19 [30,6] 3 14 
SDT_Path18 C6S5380—[0]--…—C6S764—[1, 2] 14 [0.16,0.84] 4 [7,39] 2 2 
SDT_Path19 C6S5380—[2]--…--C22S1809—[2] 13 [0.67,0.33] 2 [25,12] 1 0 
SDT_Path20 C6S5380—[0]--…—C11S5926—[1] 12 [0.06,0.94] 8 [0,8] 3 6 
SDT_Path21 C6S5380—[0]--…—C9S3563—[2] 12 [0.15,0.85] 2 [10,58] 1 1 
SDT_Path22 C6S5380—[0]--…—C1S2069—[2] 10 [0.69,0.31] 9 [21,9] 2 3 
SDT_Path23 C6S5380—[1]--…—C8S5023—[2] 9 [0.16,0.84] 6 [3,18] 1 2 
SDT_Path24 C6S5380—[0]--…—C20S2249—[1, 2] 9 [0.11,0.89] 10 [3,28] 2 4 
SDT_Path25 C6S5380—[0]--…—C19S5128—[2] 9 [0.86,0.14] 15 [27,4] 3 12 
SDT_Path26 C6S5380—[0]--…—C14S1880—[1] 9 [0.88,0.12] 18 [19,2] 3 14 
SDT_Path27 C6S5380—[0]--…—C7S397—[2] 8 [0.2,0.8] 5 [4,18] 2 3 
SDT_Path28 C6S5380—[0]--…—C1S2631—[1, 2] 8 [0.89,0.11] 16 [20,2] 3 13 
SDT_Path29 C6S5380—[0]--…—C11S5292—[1, 2] 7 [0.19,0.81] 6 [6,27] 3 4 
SDT_Path30 C6S5380—[0]--…—C12S3093—[1] 7 [0.89,0.11] 14 [21,2] 3 12 
SDT_Path31 C6S5380—[0]--…—C7S397—[1] 7 [0.48,0.52] 5 [11,12] 2 3 
SDT_Path32 C6S5380—[1]--…—C15S1347—[1, 2] 7 [0.04,0.96] 4 [0,13] 1 2 
SDT_Path33 C6S5380—[0]--…—C19S56—[2] 5 [0.04,0.96] 7 [0,15] 3 5 
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Table 18 (continued) 
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SDT_Path34 C6S5380--[0]--...--C10S2157--[1, 2] 4 [0.15,0.85] 10 [2,14] 3 8 
SDT_Path35 C6S5380--[0]--...--C9S1219--[1, 2] 4 [0.21,0.79] 12 [3,13] 3 10 
SDT_Path36 C6S5380--[0]--...--C1S716--[1, 2] 3 [0.13,0.87] 10 [3,24] 3 7 
SDT_Path37 C6S5380--[0]--...--C1S716--[0] 3 [0.58,0.42] 10 [10,7] 3 7 
SDT_Path38 C6S5380--[0]--...--C9S3331--[1, 2] 3 [0.2,0.8] 11 [3,14] 3 9 
SDT_Path39 C6S5380--[0]--...--C19S4493--[1] 2 [0.97,0.03] 18 [18,0] 3 13 
SDT_Path40 C6S5380--[0]--...--C5S3215--[1] 2 [0.24,0.76] 13 [4,14] 3 11 
SDT_Path41 C6S5380--[0]--...--C11S5926--[2] 2 [0.94,0.06] 8 [8,0] 3 6 
SDT_Path42 C6S5380--[1]--...--C17S4431--[1, 2] 2 [0.23,0.77] 7 [6,22] 1 3 
 
5.2.2.2 Model assessment on SSD 
All of the paths in SDT5 contained known causal variables in them, and all but one also had rare 
variables (Table 18). 
The largest patient subgroup found (SDT_Path1 in Table 18) had ambiguous disease 
prediction. The lack of good predictors for this large group is reflected in the modest AUC of 
SDT5. However, there were smaller groups – for example: SDT_Path11, SDT_Path14, 
SDT_Path17, SDT_Path11, SDT_Path25 – which had much stronger predictive value for 
patient-based subgroups, with a mixture of causal and rare variants. 
5.2.2.3 Summary of PDTA performance on SSD 
The best model obtained by applying PDTA on SSD did not have very good scores overall: AUC 
= 0.59 (95% CI: 0.561-0.620), F1 = 0.6, PPV = 0.1. A closer look at the paths showed poor 
performance for subgroups characterizing large sections of the population, but several pockets of 
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good prediction for smaller groups. Even though the SDT appears to be a population-wide tree, 
as compared to the PS paths created in a final PDT, it is actually prioritizing individualized 
groups fairly well.   
The observations on SBD made me doubt the value of MSR in selecting the best model; 
the observations on SSD further validated my suspicions. For all following experiments on 
genomic datasets, MSR was no longer used in model selection. 
 
5.2.3 Evaluation of refined algorithm on WE-CP 
5.2.3.1 Empirical Optimization of PDT on WE-CP and WE-CPR 
In all datasets examined so far, the number of nodes in the SDT rose monotonically with ENP, 
which leads to longer runtimes for the algorithm. Since WE-CP is a very large dataset, the search 
for the best SDT was applied to WE-CP with a small set of low ENP values (Table 19). For these 
values, none of the SDTs formed trees with more than 3 or 4 nodes. Therefore, the experiments 
were repeated on a subset of WE-CP with reduced dimensionality (WE-CP-R) (see Section 
4.1.4), along with additional higher values of ENP (Table 20). 
Despite the reduced dimensionality of WE-CP-R compared to WE-CP, the parameter 
value ENP = 1 failed to produce full trees with more than 3 or 4 nodes. However, at higher ENP 
values, better SDTs were formed, with most of the higher AUC models including all available 
SNVs as nodes (Table 21). The best AUC achieved was 0.57 (95% CI: 0.528-0.62). Choosing 
the best model by prioritizing high AUC with smaller SDT size, the parameters for SDT2 in 
Table 21 were applied to test PDTA on WE-CP-R (Table 22). 
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Table 19: Hyperparameter settings used in SDTA on WE-CP 
 
 
 
Table 20: Hyperparameter settings used in SDTA on WE-CP-R 
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Table 21: 10 best SDTs on WE-CP-R, ranked by highest AUC 
 
Model AUC 95% CI      MSR α ENP # of        
leaves 
# of         
nodes 
SDT1 0.574 0.528-0.620 0.985 0.1 500 520 516 
SDT2 0.570 0.513-0.627 0.872 50 100 319 153 
SDT3 0.565 0.510-0.621 0.977 0.5 500 520 516 
SDT4 0.564 0.518-0.610 0.987 0.001 500 519 516 
SDT5 0.564 0.510-0.618 0.972 10 500 1104 516 
SDT6 0.557 0.506-0.607 0.990 50000 500 1150 516 
SDT7 0.555 0.501-0.610 0.872 10 200 241 123 
SDT8 0.553 0.507-0.599 0.989 0.005 500 520 516 
SDT9 0.553 0.500-0.606 0.780 1 100 57 54 
SDT10 0.553 0.521-0.585 0.842 0.5 100 36 35 
 
 
Table 22: Results of PDTA on WE-CP-R with best SDT parameters 
(SDT2 in Table 21) 
 
Model α Tree 
ENP 
Path 
ENP 
# times 
PS chosen 
(out of 
427) 
SDT 
AUC 
95% CI 
(Delong) 
PDT 
AUC 
95% CI 
(Delong) 
PDT1 50 100 1 0 0.570 0.513-0.627 0.570 0.513-0.627 
PDT2 50 100 100 0 0.570 0.513-0.627 0.570 0.513-0.627 
PDT3 50 100 200 0 0.570 0.513-0.627 0.570 0.513-0.627 
PDT4 50 100 300 3 0.570 0.513-0.627 0.568 0.512-0.625 
PDT5 50 100 400 19 0.570 0.513-0.627 0.574 0.517-0.630 
PDT6 50 100 450 42 0.570 0.513-0.627 0.585 0.529-0.642 
PDT7 50 100 500 42 0.570 0.513-0.627 0.585 0.529-0.642 
 
5.2.3.2 Model assessment on WE-CP-R 
The best SDT model contained rare variables in many of its paths (Table 23). At the PS path 
creation phase, the number of PS paths increased with the value of path ENP, with AUC rising 
slightly at the higher path ENPs (Table 22). The model with the highest AUC was PDT6, where, 
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42 out of 427 test instances selected one of 39 individual PS paths. However, all of the PS paths 
included all 516 SNVs as nodes, failing to generalize to more than 1 or 2 test instances each, and 
had near ambiguous (~50%) disease prediction. Therefore, I conclude that the PS paths are not 
useful for finding patient subgroups, and instead proceed with the subgroups found when all test 
instances chose a path in the SDT. This was the case in PDT1, PDT2 and PDT3: 110 unique 
paths in their SDT were selected by the 427 test instances. The largest subgroup had 127 
patients; the smallest (39 subgroups) had 1. The top 8 most frequently selected paths are shown 
in Table 23. Since all of these subgroups are from the same tree, they share the same root node, 
rs7332962. The 5 largest patient subgroups are detailed in Tables 24-28. The interrelationship of 
these 5 paths is shown in Figure 20. 
 86 
Table 23: Top 8 SDT paths selected by test samples of WE-CP-R (out of 110) 
ranked by frequency (PDT1 of Table 2) 
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SDT_Path1 rs7332962--[0, 2]--...--rs79636164--[0] 127 [0.3,0.7] [38,89] 19 [132,313] 14 
SDT_Path2 rs7332962--[0, 2]--...--rs17107315:[36,56]--[0, 2] 20 [0.36,0.64] [7,13] 16 [32,56] 10 
SDT_Path3 rs7332962--[0, 2]--...--rs12919410:[32,39]--[1, 2] 15 [0.35,0.65] [5,10] 12 [19,36] 5 
SDT_Path4 rs7332962--[0, 2]--…--rs11628525:[13,100]--[0] 10 [0.0,1.0] [1,9] 10 [0,34] 5 
SDT_Path5 rs7332962--[0, 2]--...--rs4764427:[7,45]--[1] 9 [0.0,1.0] [1,8] 13 [0,21] 5 
SDT_Path6 rs7332962--[0, 2]--…--rs17702641:[6,56]--[0] 7 [0.0,1.0] [2,5] 16 [0,25] 5 
SDT_Path7 rs7332962--[0, 2]--...--rs2854128:[8,31]--[2] 7 [0.0,1.0] [3,4] 22 [0,18] 9 
SDT_Path8 rs7332962--[0, 2]--...--rs291096:[10,43]--[0] 7 [0.01,0.99] [1,6] 20 [0,12] 9 
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Figure 20: Interrelation of the 5 patient subgroups highlighted in Tables 24-28 
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The most commonly chosen path, SDT_Path1 in Table 23, correctly predicted presence 
of disease in 89 out of 127 patients. The path is comprised of 19 SNVs, out of which 14 are rare 
SNVs. Few of the SNVs have known functional consequence and clinical significance from 
dbSNP (Table 24). However, a review of the literature shows many of these SNVs or their 
associated genes have roles in pancreas related function. GABRP, MUC16, MAP1S, MEGF6, 
ARHGAP24, and OR1L3 have all been shown to be associated with pancreatic cancer, a 
common late stage consequence of CP86-95. Out of these, in this patient subgroup, only the SNV 
GABRP shows mutation in its emergent branch (Node #1, Table 24). The others having been 
selected as predictive nodes with major homozygous (no mutation) emergent edges, for this 
patient subgroup, indicates that there are other patient subgroups where they are predictive in the 
mutated state. 
The CFTR gene has many variants that are pathogenic for CP29 and the variant in this 
patient subgroup, rs1801178, is predicted to be deleterious by SIFT/Polyphen96 although in this 
particular patient subgroup, it is not mutated. RHBDL3 plays a role in pancreatic development97 
and PIK3R6 has been implicated in Type II diabetes98. Both genes have mutated variants in this 
patient subgroup. 
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Table 24: SNVs in SDT_Path1 on WE-CP-R  
with known functional consequence and clinical significance from dbSNP 
(*) Indicates a gene with known or suspected role in pancreas related function or disorder 
 
 Node SNP Edge Functional 
consequence 
Clinical 
significance 
Associated 
Gene 
Node Count Global MAF 
(TOPMED) 
root rs7332962 [0, 2] intron variant                                   NA CENPJ        
RNF17 
[572,1136] T=0.0718/9022 
1 rs975061 [0, 2] synonymous 
codon 
NA GABRP            * [497,1077] T=0.0478/6001 
2 rs1801178 [0]   Likely benign 
(for cystic 
fibrosis) 
CFTR                * 
CFTR-AS1 
[467,1054] G=0.00007/9 
3 rs16840899 
 
[0] Missense NA SORCS2 [459,981] T=0.0184/2305 
4 rs2624901 
 
[1, 2] intron variant NA KIAA1257 [451,981] T=0.4512/56652 
5 rs7212413 [0, 1]   NA   [335,635] A=0.1594/20014 
6 rs148585362 
 
[0] Missense NA MUC16           * [335,620] C=0.0021/262 
7 rs1443486 [0, 2, 
3] 
intron variant, 
upstream 
variant 2KB 
NA LOC105371731 
RHBDL3          * 
[330,620] G=0.4507/56590 
8 rs4310906 
 
[0, 1] intron variant NA PIK3R6            * [155,363] A=0.0825/10360 
9 rs6970210 [0] intron variant, 
missense 
NA INMT-MINDY4   
INMT 
[152,363] G=0.0419/5259  
10 rs292501 [0, 1] intron variant, 
missense, syn 
codon, utr 
variant 3 prime 
NA C7orf49   
TMEM140 
[152,348] T=0.0891/446 
11 rs73116843 [0, 1] intron variant NA ANKRD31 [149,348] T=0.0514/6457 
12 rs16970731 [0] intron variant NA GPATCH8 [146,348] A=0.0410/5152 
13 rs77093026 [0] missense, nc 
transcript 
variant 
NA LOC105372299   
MAP1S 
[145,340] A=0.0284/3568 
14 rs61746548 
 
[0] Missense NA MEGF6            * [140,339] T=0.0472/5933 
15 rs10493753 [0, 1] missense, nc 
transcript 
variant 
NA SPATA1  [140,326] C=0.0998/12528 
16 rs1482097 
 
[0] intron variant NA ARHGAP24     * [137,326] A=0.1100/13810 
17 rs1799980 
 
[0] Missense Benign SCNN1B [137,313] T=0.0398/4993 
18 rs79636164 
 
[0] Missense NA OR1L3             * [134,313] T=0.0631/7928 
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The second most commonly chosen path, SDT_Path2 in Table 23, correctly predicted 
disease in 13 out of 20 patients (Table 25). The path is comprised of 16 SNVs, out of which 10 
are rare SNVs. The terminal node in this path is (wildtype and biallelic mutant) rs17107315, also 
known as the N34S variant in SPINK, a well-known risk factor for CP99. 
For the first 4 nodes, SDT_Path2 is the same as SDT_Path1; they diverge at rs2624901, 
which branches with mutated alleles in SDT_Path1, and wildtype allele in SDT_Path2. The 
remaining SNPs in SDT_Path2 are distinct from those in SDT_Path1. Again, few of the SNVs 
have known functional consequence and clinical significance from dbSNP (Table 25), but a 
review of the literature shows some of them or their associated genes have roles in pancreas 
related function. In addition to GABRP and CFTR, which have variants in the portion of the path 
common to SDT_Path1, SDT_Path2 also includes SNVs associated with STAT5A, PCNT, and 
HYOU1 which have been shown to have roles in pancreatic endocrine function100-103. Out of 
these, the SNV associated with STAT5A is heterozygous for this patient subgroup. Another SNV 
in this patient group is associated with gene ECM1, which may have a role in pancreatic 
cancer104. 
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Table 25: SNVs in SDT_Path2 on WE-CP-R 
with known functional consequence and clinical significance from dbSNP 
(*) Indicates a gene with known or suspected role in pancreas related function or disorder 
 
  SNP Edge 
Functional 
consequence 
Clinical 
significance 
Associated 
Gene 
Node 
Count 
Global MAF 
(TOPMED) 
root rs7332962 [0, 2] intron variant NA CENPJ, RNF17 [572,1136] T=0.0718/9022 
1 rs975061 [0, 2] 
synonymous 
codon NA GABRP           * [497,1077] T=0.0478/6001 
2 rs1801178 [0]   
Likely benign 
in cystic 
fibrosis 
CFTR,              * 
CFTR-AS1 [467,1054] G=0.00007/9 
3 rs16840899 [0] Missense NA SORCS2 [459,981] T=0.0184/2305 
4 rs2624901 [0] intron variant NA KIAA1257 [451,981] T=0.4512/56652 
5 rs2293158 [0, 1] intron variant NA STAT5A          * [115,346] C=0.2950/37044 
6 rs2553311 [0, 1]   NA   [96,326] A=0.4150/52113 
7 rs60078675 [0] Missense Likely benign PCNT              * [80,226] T=0.0224/2814 
8 rs76042396 [0] Missense NA DNASE2B [78,226] A=0.0360/4517 
9 rs604630 [0] Missense NA CTSW [76,226] A=0.0674/8464 
10 rs11822958 [0] 
nc transcript 
variant, 
synonymous 
codon NA HYOU1           * [76,215] T=0.0476/5982 
11 rs6735208 [0, 1] Missense 
With other 
allele (in 
nemaline 
myopathy) NEB [74,215] T=0.3268/41030 
12 rs73721657 [0] Missense NA KCP [74,204] T=0.0557/6998 
13 rs435004 [0] intron variant NA ST6GALNAC3 [72,204] T=0.0932/11699 
14 rs3737240 [0] Missense NA ECM1             * [72,195] T=0.2823/35446 
15 rs17107315 [0, 2] Missense 
With other 
allele (in 
chronic 
pancreatitis) SPINK1           * [36,56] C=0.0070/885 
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The third most commonly chosen path, SDT_Path3 in Table 23, correctly predicted 
disease in 10 out of 15 patients (Table 26). The path is comprised of 12 SNVs, out of which 5 are 
rare SNVs. This path shares its first 4 nodes with the previous two patient subgroups, and then 
the next 3 nodes with SDT_Path1. This common portion of the path contains variants associated 
with MUC16, CFTR and GABRP. It diverges from SDT_Path1 at rs1443486, which branches 
with the heterozygous variant to continue on SDT_Path3. This SNV is associated with gene 
RHBDL3, which plays a role in pancreatic development 97. The full list of nodes in SDT_Path3 
are shown in Table 26, along with information from dbSNP. 
 
Table 26: SNVs in SDT_Path3 on WE-CP-R 
with known functional consequence and clinical significance from dbSNP 
(*) Indicates a gene with known or suspected role in pancreas related function or disorder 
  SNP Edge 
Functional 
consequence 
Clinical 
significance 
Associated 
Gene 
Node 
Count 
Global MAF 
(TOPMED) 
root rs7332962 [0, 2] intron variant                                   NA 
CENPJ        
RNF17 [572,1136] T=0.0718/9022 
1 rs975061 [0, 2] 
synonymous 
codon NA GABRP          * [497,1077] T=0.0478/6001 
2 rs1801178 [0]   
Likely benign 
(cystic 
fibrosis) 
CFTR             * 
CFTR-AS1 [467,1054] G=0.00007/9 
3 rs16840899 [0] missense NA SORCS2 [459,981] T=0.0184/2305 
4 rs2624901 [1, 2] intron variant NA KIAA1257 [451,981] T=0.4512/56652 
5 rs7212413 [0, 1]   NA   [335,635] A=0.1594/20014 
6 rs148585362 [0] missense NA MUC16         * [335,620] C=0.0021/262 
7 rs1443486 [1] 
intron variant, 
upstream 
variant 2KB NA 
LOC105371731 
RHBDL3        * [330,620] G=0.4507/56590 
8 rs5920097 [0]   NA   [175,257] T=0.2594/32574 
9 rs3860455 [1] intron variant NA NPAS2 [102,192] T=0.3128/39273 
10 rs2832007 [0, 1] intron variant NA N6AMT1 [38,39] A=0.3952/49626 
11 rs12919410 [1, 2]   NA   [32,39] T=0.4272/53641 
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The fourth most commonly chosen path, SDT_Path4 in Table 23, correctly predicted 
disease in 9 out of 10 patients (Table 27). The path is comprised of 10 SNVs, out of which 5 are 
rare SNVs. This path shares its first 4 nodes with the previous three patient subgroups, branches 
off at rs2624901 with SDT_Path2, then branches off from SDT_Path2 at rs2553311 with minor 
homozygous allele. The full list of nodes and known functional consequence and clinical 
significance from dbSNP (Table 27) do not show any relationship to CP, but a review of the 
literature shows HYAL4 and SIPA1L1 may be involved in cancer progression 105,106. 
 
Table 27: SNVs in SDT_Path4 on WE-CP-R  
with known functional consequence and clinical significance from dbSNP 
(*) Indicates a gene with known or suspected role in pancreas related function or disorder 
 
  SNP Edge Functional 
consequence 
Clinical 
significance 
Associated 
Gene 
Node 
Count 
Global MAF 
(TOPMED) 
root rs7332962 [0, 2] intron 
variant                                   
NA CENPJ        
RNF17 
[572,1136] T=0.0718/9022 
1 rs975061 [0, 2] synonymous 
codon 
NA GABRP            * [497,1077] T=0.0478/6001 
2 rs1801178 [0] intron 
variant 
missense 
Likely benign 
(cystic fibrosis) 
CFTR                * 
CFTR-AS1 
[467,1054] G=0.00007/9 
3 rs16840899 [0] missense NA SORCS2 [459,981] T=0.0184/2305 
4 rs2624901 
[0] 
intron 
variant 
NA KIAA1257 [451,981] T=0.4512/56652 
5 rs2293158 
[0, 1] 
intron 
variant NA STAT5A           * [115,346] C=0.2950/37044 
6 rs2553311 [2]   NA   [96,326] A=0.4150/52113 
7 
rs17031662 [0] 
intron 
variant NA 
LOC105369938 
MYBPC1 [15,100] T=0.1107/13900 
8 
rs10264078 [0] 
intron 
variant NA HYAL4             * [14,100] G=0.0584/7327 
9 
rs11628525 [0] 
intron 
variant NA SIPA1L1          * [13,100] G=0.3293/41355 
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The fifth most commonly chosen path, SDT_Path5 in Table 23, correctly predicted 
disease in 8 out of 9 patients. The path is comprised of 13 SNVs, out of which 5 are rare SNVs. 
This patient subgroup shares the entire path of SDT_Path4 until its final node rs11628525, where 
SDT_Path5 branches off with the mutant variant, then continues for three more nodes (Table 28). 
The SNV rs1162525 is associated with SIPAIL1, which may be implicated in pancreatic 
cancer106. 
 
Table 28: SNVs in SDT_Path5 on WE-CP-R 
with known functional consequence and clinical significance from dbSNP 
(*) Indicates a gene with known or suspected role in pancreas related function or disorder 
 
 
  SNP Edge Functional 
consequence 
Clinical 
significance 
Associated 
Gene 
Node 
Count 
Global MAF 
(TOPMED) 
root rs7332962 [0,2] intron 
variant                                   
NA CENPJ        
RNF17 
[572,1136] T=0.0718/9022 
1 rs975061 [0,2] synonymous 
codon 
NA GABRP            * [497,1077] T=0.0478/6001 
2 rs1801178 [0] intron 
variant 
missense 
Likely benign 
(cystic fibrosis) 
CFTR                * 
CFTR-AS1 
[467,1054] G=0.00007/9 
3 rs16840899 [0] missense NA SORCS2 [459,981] T=0.0184/2305 
4 rs2624901 
[0] 
intron 
variant 
NA KIAA1257 [451,981] T=0.4512/56652 
5 
rs2293158 [0,1] 
intron 
variant NA STAT5A           * [115,346] C=0.2950/37044 
6 rs2553311 [2]   NA   [96,326] A=0.4150/52113 
7 
rs17031662 [0] 
intron 
variant NA 
LOC105369938 
MYBPC1 [15,100] T=0.1107/13900 
8 
rs10264078 [0] 
intron 
variant NA HYAL4             * [14,100] G=0.0584/7327 
9 
rs11628525 [1,2] 
intron 
variant NA SIPA1L1          * [13,100] G=0.3293/41355 
10 rs12549155 [1,2] 
intron 
variant NA LOC105375706 [13,66] A=0.4049/50845 
11 rs217190 [0] 
intron 
variant NA ABLIM1 [13,48] G=0.2279/28612 
12 rs4764427 [1] 
intron 
variant NA LOC102724227 [7,45] A=0.4589/57623 
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5.2.3.3 Summary of PDTA performance on WE-CP-R 
When PDTA was applied to WE-CP, only lower ENP values were used. This was due to the 
great computational burden of large trees that would be created at high ENP for a dataset of this 
magnitude. Upon reducing the number of variables, PDTA was able to build models with AUC = 
0.57 (95% CI: 0.513-0.627), within which several patient-specific subgroups were discovered. 
These subgroups included many rare variants. Although few of the predictors in these subgroups 
were found in databases of known pathogenic variants, many were found to have associations 
with genes that are under investigation for pancreas related issues. Therefore, some of the rare 
variants discovered by PDTA may be novel variants. 
5.2.4 Evaluation of refined algorithm on WE-DB 
5.2.4.1 Empirical Optimization of PDT on WE-DB 
The final dataset used to evaluate PDTA was the WE-DB. This is a subset of patient samples 
from the WE-CP dataset, containing only the cases which were positive for CP/RAP (see Section 
4.1.5). Consequently, the number of instances is much lower, while the number of SNVs is 
comparable to that in WE-DB. I expected, as seen in WE-CP, that low ENP values would not be 
good for tree building. However, high ENP values lead to very long runtimes for a dataset of this 
size. Therefore, SDTA was applied to WE-DB with the hyperparameter settings in Table 29. As 
expected, the lower ENP values (ENP = 1, 20, 50) failed to form trees with more than 3 or 4 
nodes. For higher ENP values, larger trees are formed, but even the largest SDT was comprised 
of 79 nodes (SDT5 in Table 30; α = 10, ENP = 10,000) – a substantially tractable number of 
variables for WE-DB, which contains 245,573 variables. 
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Table 29: Hyperparameter settings used in SDTA on WE-DB 
 
 
 
 
Table 30: 10 best SDTs on WE-DB, ranked by highest AUC 
 
Model SDT 
AUC 
95% CI MSR α ENP # of 
leaves 
# of 
nodes 
SDT1 0.570 0.507-0.633 0.560 5000 500 23 9 
SDT2 0.570 0.501-0.640 0.551 10 1000 76 65 
SDT3 0.566 0.496-0.636 0.375 50 100 14 7 
SDT4 0.556 0.491-0.621 0.667 10 5000 103 76 
SDT5 0.555 0.490-0.620 0.693 10 10000 112 79 
SDT6 0.555 0.496-0.613 0.478 1 1000 21 18 
SDT7 0.550 0.484-0.615 0.576 5000 1000 31 13 
SDT8 0.547 0.487-0.608 0.481 0.1 1000 25 24 
SDT9 0.547 0.487-0.608 0.481 0.05 1000 25 24 
SDT10 0.547 0.487-0.608 0.481 0.01 1000 25 24 
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SDT1 in Table 30 achieved the highest AUC, building a tree with 9 nodes. Choosing this 
as the best model, its parameter values were applied to test PDTA on WE-DB (Table 31). Even 
with a fairly high path ENP, PDTA failed to produce any PS paths on this dataset. Therefore, I 
continue with SDT1 as the best model. 
 
 
Table 31: Results of PDTA on WE-DB with best SDT parameters  
(SDT1 in Table 30) 
 
 
Model α tree 
ENP 
path 
ENP 
# of times PS 
chosen (out of 
283) 
SDT 
AUC 
95% CI PDT 
AUC 
95% CI 
PDT1 5000 500 500 0 0.570  0.507-0.633 0.570  0.507-0.633 
PDT2 5000 500 1000 0 0.570  0.507-0.633 0.570  0.507-0.633 
 
 
5.2.4.2 Model assessment on WE-DB 
The paths in the SDT of the best model, SDT1 in Table 30, were dominated by rare variants 
(Table 32). 15 unique paths in the SDT were selected by the 283 test samples, but only the most 
frequently selected path, SDT_Path1, had an unambiguous disease prediction. Therefore, I 
conclude that the SDT_Path1 is the only clearly defined patient subgroup we can get from this 
model.
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Table 32: SDT paths selected by test samples of WE-DB, ranked by frequency 
(SDT1 of Table 30) 
Path   #
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SDT_Path1 rs1500701--[0]--...--rs114883808--[0] 209 [0.75,0.25] [162,47] 9 [731,167] 8 
SDT_Path2 rs1500701--[1]—leaf 15 [0.49,0.51] [11,4] 1 [21,25] 1 
SDT_Path3 rs1500701--[0]--...--rs10069511--[1] 14 [0.5,0.5] [10,4] 3 [18,19] 3 
SDT_Path4 rs1500701--[0]--...--rs41266136--[1] 11 [0.5,0.5] [9,2] 6 [23,21] 6 
SDT_Path5 rs1500701--[0]--...--rs61741082--[1] 8 [0.5,0.5] [3,5] 5 [10,8] 5 
SDT_Path6 rs1500701--[0]--...--rs2234256--[1] 6 [0.5,0.5] [2,4] 4 [11,12] 4 
SDT_Path7 rs1500701--[0]--...--rs72634778--[1] 6 [0.48,0.52] [3,3] 7 [4,11] 7 
SDT_Path8 rs1500701--[0]--...--rs74452694--[2] 6 [0.49,0.51] [3,3] 8 [4,8] 7 
SDT_Path9 rs1500701--[0]--...--rs114883808--[1] 2 [0.5,0.5] [1,1] 9 [6,8] 8 
SDT_Path10 rs1500701--[3]—leaf 1 [0.5,0.5] [0,1] 1 [0,0] 1 
SDT_Path11 rs1500701--[0]--...--rs74452694--[3] 1 [0.5,0.5] [1,0] 8 [0,0] 7 
SDT_Path12 rs1500701--[0]--...--rs61741082--[2] 1 [0.5,0.5] [1,0] 5 [0,1] 5 
SDT_Path13 rs1500701--[0]--...--rs2234256--[2] 1 [0.5,0.5] [1,0] 4 [0,2] 4 
SDT_Path14 rs1500701--[0]--rs73277460--[1] 1 [0.49,0.51] [1,0] 2 [7,12] 2 
SDT_Path15 rs1500701--[0]--...--rs10069511--[3] 1 [0.5,0.5] [1,0] 3 [0,1] 3 
 
 
SDT_Path1 was chosen for 209 out of the 283 test samples, and it correctly predicted the 
absence of disease in 162 of them. 8 out of the 9 SNVs comprising nodes in SDT_Path1 are rare 
variables.  The known information from dbSNP on functional consequence and clinical 
significance of the SNVs in SDT_Path1 do not show any connection to pancreatic function or 
disorder (Table 33). However, mutations in the CTAGE5 gene, associated with the second SNV 
in this path, rs73277460, is known to interfere with proinsulin trafficking 107. This is consistent 
with the absence of mutation in rs73277460 in SDT_Path1, which predicts absence of disease. 
This subgroup also includes SNVs with are associated with HRNR and HNRNPH1 which may 
play a role in pancreatic cancer 108,109. 
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Table 33: SNVs in SDT_Path1 on WE-DB 
with known functional consequence and clinical significance from dbSNP 
(*) Indicates a gene with known or suspected role in pancreas related function or disorder 
  SNP Edge 
Functional 
consequence 
Clinical 
significance 
Associated 
Gene 
Node 
Count 
Global MAF 
(TOPMED) 
root rs1500701 [0] intron variant NA EPHA6 [837,300] G=0.0649/8144 
1 rs73277460 [0] 
missense, nc transcript 
variant NA CTAGE5       * [816,274] G=0.0209/2622 
2 rs10069511 [0] intron variant NA LINC01933 [809,261] A=0.0289/3625 
3 rs2234256 [0] 
intron variant, 
missense, upstream 
variant 2KB 
Association: 
Alzheimer's 
disease 
LOC105375056, 
TREM2, 
TREML1 [790,241] G=0.0413/5186 
4 rs61741082 [0] missense NA CHTF18 [778,227] C=0.0366/4599 
5 rs41266136 [0] missense NA HRNR           * [768,217] T=0.0162/2033  
6 rs72634778 [0] 
missense, nc transcript 
variant, upstream 
variant 2KB, utr variant 
5 prime NA 
LOC107984912, 
ZBTB48 [745,195] A=0.0059/735 
7 rs74452694 [0, 1] 
intron variant, 
upstream variant 2KB, 
utr variant 5 prime NA HNRNPH1    * [741,184] T=0.1005/12616 
8 rs114883808 [0] 
intron variant, 
missense NA 
LOC101928583, 
SLC7A14 [737,176] T=0.0072/904 
 
5.2.4.3 Empirical Optimization of PDT on WE-DB-R 
In the case of WE-CP, the use of a lower dimensional dataset resulted in better performance of 
PDTA. Therefore, I used the same method to create a lower dimensional dataset from WE-DB, 
WE-DB-R (see Section 4.1.5), to see if PDTA will give better results. First, SDTA was applied 
to WE-DB-R with the hyperparameter settings shown in Table 34. 
As seen in previous cases, raising the value of ENP created larger trees, and in general 
higher ENPs and higher α resulted in better AUCs (Table 35). SDT1 achieved the best AUC at 
0.62 (95% CI: 0.545-0.690), but it recruited all 638 available SNVs as nodes, thereby lowering 
its value as predictor of patient subgroups (Table 35). The next highest ranked model, SDT2, was 
built using 42 nodes, and had an AUC of 0.61 (95% CI: 0.553-0.672); as the smaller tree without 
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much loss in predictive power, this was selected as the best model to proceed with the next phase 
of PDTA (Table 36). 
 
Table 34: Hyperparameter settings used in SDTA on WE-DB-R 
 
 
Table 35: 10 best SDTs on WE-DB-R, ranked by highest AUC 
Model AUC 95% CI MSR α ENP # of 
leaves 
# of 
nodes 
SDT1 0.617 0.5449-0.6892 0.994 50000 400 1344 638 
SDT2 0.613 0.5531-0.672 0.967 10000 200 89 42 
SDT3 0.611 0.5515-0.6696 0.973 50000 200 148 61 
SDT4 0.608 0.5513-0.6654 0.923 10000 100 50 22 
SDT5 0.596 0.5243-0.6682 0.986 1000 400 1321 638 
SDT6 0.596 0.5228-0.6683 0.957 1000 200 413 178 
SDT7 0.591 0.5201-0.6628 0.904 100 100 279 132 
SDT8 0.591 0.5199-0.6623 0.918 100 200 329 154 
SDT9 0.590 0.5208-0.6601 0.673 1000 50 50 24 
SDT10 0.590 0.5207-0.6602 0.980 1 400 646 638 
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Table 36: Results of PDTA on WE-DB-R with best SDT parameters 
(SDT2 in Table 35) 
 
Model α Tree 
ENP 
Path 
ENP 
# of times 
PS (out of 
283) 
SDT 
AUC 
95% CI PDT 
AUC 
95% CI 
PDT1 10000 200 1 0 0.613 0.5531-0.672 0.613 0.553-0.672 
PDT2 10000 200 100 0 0.613 0.5531-0.672 0.613 0.553-0.672 
PDT3 10000 200 200 0 0.613 0.5531-0.672 0.613 0.553-0.672 
PDT4 10000 200 400 71 0.613 0.5531-0.672 0.605 0.542-0.667 
 
5.2.4.4 Model assessment on WE-DB-R 
PS paths were produced only in PDT4 of Table 36, which had the highest path ENP setting, but 
all the PS paths selected all 638 SNVs as nodes, thus failing to produce patient subgroups. 
Therefore, I proceed with SDT2 of Table 35 as the best model. 31 unique paths were selected by 
the 283 test samples, and all of them contained rare SNVs. However, just as was the case in WE-
DB, only the most frequently selected path, SDT_Path1 (Table 37) had an unambiguous disease 
prediction. Therefore, SDT_Path1 is the only clearly defined patient subgroup we can get from 
this model. 
SDT_Path1 was chosen for 233 of the 283 test samples, and it correctly predicted the 
absence of disease in 184 of them. The information from dbSNP on functional consequence and 
clinical significance of the SNVs in SDT_Path1 do not show any relation to pancreatic function 
or disorder (Table 38). However, there were numerous genes associated with SNVs in this 
patient group which have been implicated in pancreas related diseases. TBC1D31 is involved in 
β-cell replication110; CENPF may be disrupted in islet cells in diabetes111; ESRRG is involved in 
regulation of β-cell maturation112. There were also several genes in this subgroup – MUC6, 
TPD52, MMP1, FBXW8, C5, PALB – that have been investigated for a possible role in 
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pancreatic cancer88,89,113-117 though the predictor for this task was for the presence or absence of 
diabetes, if genetic markers for pancreatic cancer in CP patients are in a subgroup that is not 
likely to develop diabetes, there may be a mechanistic connection that relates the co-occurrence 
of pathogenic/protective variants. 
 
Table 37: Top 8 SDT paths selected by test samples of WE-DB-R (out of 31) 
ranked by frequency (SDT2 of Table 35)  
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SDT_Path1 
rs199833698:[837,300]--[0]--...--
rs17043116:[783,192]--[0, 1, 3] 233 [0.77,0.23] [184,49] 27 [781,190] 22 
SDT_Path2 
rs199833698:[837,300]--[0]--...--
rs55959319:[787,204]--[1] 4 [0.5,0.5] [3,1] 18 [1,2] 16 
SDT_Path3 
rs199833698:[837,300]--[0]--...--rs2081807:[8,10]--
[2] 3 [0.47,0.53] [2,1] 4 [0,8] 3 
SDT_Path4 
rs199833698:[837,300]--[0]--…--
rs7086208:[789,210]--[2] 3 [0.49,0.51] [2,1] 14 [0,2] 12 
SDT_Path5 
rs199833698:[837,300]--[1]--...--rs73507220:[8,4]--
[1] 3 [0.49,0.51] [1,2] 3 [0,2] 2 
SDT_Path6 
rs199833698:[837,300]--[0]--…rs12614237:[13,13]-
-[0] 3 [0.51,0.49] [3,0] 5 [2,0] 4 
SDT_Path7 
rs199833698:[837,300]--[0]--...--rs11762428:[6,2]--
[1] 2 [0.49,0.51] [1,1] 5 [0,2] 3 
SDT_Path8 
rs144825978:[796,241]--[0]--…--
rs76280974:[783,196]--[1] 2 [0.5,0.5] [1,1] 23 [0,1] 18 
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Table 38: SNVs in SDT_Path1 on WE-DB-R 
with known functional consequence and clinical significance from dbSNP 
(*) Indicates a gene with known or suspected role in pancreas related function or disorder 
 
  SNP Edge Functional 
consequence 
Clinical 
significance 
Associated 
Gene 
Node 
Count 
Global MAF 
(TOPMED) 
root rs199833698 [0] Missense NA MUC6        * [837,300] A=0.0314/3949 
1 rs75916244 [0] 
missense, nc transcript 
variant, synonymous 
codon NA APOO [823,280] C=0.0227/2851 
2 rs80284803 [0] Missense NA HYDIN [818,269] G=0.000008/1 
3 rs2230795 [0] 
missense, nc transcript 
variant Likely benign 
ELP1,      
IKBKAP [810,257] T=0.0359/4502 
4 rs146538633 [0] 
intron variant,missense, 
upstream variant 2KB, utr 
variant 5 prime NA 
CHTF18, 
RPUSD1 [797,244] T=0.0046/576 
5 rs144825978 [0] Missense NA 
RGAG1,    
RTL9 [796,241] T=0.0087/1090 
6 rs117461662 [0] 
intron variant, missense, 
nc transcript variant NA 
LOC105375919, 
TPD52       * [794,239] G=0.0032/404 
7 rs111534710 [0] Missense NA FAM47A [791,230] G=0.0129/1623 
8 rs200410849 [0] 
missense, upstream 
variant 2KB NA UMODL1 [791,227] C=0.0006/76 
9 rs379999 [0, 1]   NA   [791,222] C=0.0856/10744 
10 rs148980271 [0] intron variant, missense NA 
MMP1,      * 
WTAPP1 [791,219] T=0.0008/101 
11 rs114540180 [0] 
missense, splice acceptor 
variant NA GIMAP6 [791,216] C=0.0188/2362 
12 rs144993453 [0] intron variant, missense NA RBPMS [789,212] A=0.0029/366 
13 rs7086208 [0, 1] intron variant NA FRMD4A [789,210] A=0.1011/12692 
14 rs147449897 [0] 
missense, nc transcript 
variant NA FBXW8       * [789,208] G=0.0041/515 
15 rs41311881 [0] Missense NA C5               * [789,207] G=0.0052/653 
16 rs35988863 [0] Missense NA KRT71 [789,206] A=0.0131/1650 
17 rs55959319 [0] 
missense, nc transcript 
variant NA TBC1D31   * [787,204] A=0.0169/2121 
18 rs3795518 [0, 1] Missense NA CENPF        * [786,202] A=0.1179/14799 
19 rs5904862 
[0, 1, 
2] 
missense, nc transcript 
variant, syn codon NA CDKL4 [783,199] G=0.2442/30668 
20 rs11892364 [0, 1]   NA   [783,198] A=0.0174/2188 
21 rs4743820 
[0, 1, 
2] 
intron variant, upstream 
variant 2KB NA 
LINC00484, 
LOC100507103 [783,197] C=0.3941/49484 
22 rs76280974 [0] intron variant, missense NA WDR78 [783,196] C=0.0080/1005 
23 rs138789658 [0] 
missense, utr variant 5 
prime 
Uncertain 
significance PALB2         * [783,195] C=0.0054/679 
24 rs139102003 [0] Missense NA CTSO [783,194] A=0.0070/880 
25 rs75987633 [0, 1]   NA   [783,193] T=0.0300/3770 
26 rs17043116 
[0, 1, 
3] intron variant   ESRRG        * [783,192] A=0.0665/8352 
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5.2.4.5 Summary of PDTA performance on WE-DB and WE-DB-R 
The WE-DB and WE-DB-R datasets did not have a large sample size. Also, the samples were 
heavily unbalanced in favor of controls – there were almost 3 times as many controls than 
diabetic patients. This may have driven PDTA to predict the main subgroup defined by absence 
of disease rather than presence of disease. Nevertheless, PDTA found a predictive patient 
subgroup in both WE-DB and WE-DB-R, and the subgroups contained many rare SNVs. 
Reducing the variable space from WE-DB to WE-DB-R did not give us more patient subgroups, 
but gave a model with better AUC and more predictive variants. 
In the case of WE-CP, I did not test PDTA with larger ENPs. Upon testing WE-CP-R 
with larger ENPs, PDTA performed better and uncovered rare variants. Large ENPs on large 
datasets take a large amount of time to compute. The comparison of WE-DB with WE-DB-R 
works in favor of the instinct that it is not worth wasting time on pushing large and time-
consuming models, when reduced variable versions give better predictive performance while still 
finding rare variants as predictors, without the extra computational investment. 
A further consideration about WE-DB and WE-DB-R: the patients in this dataset were 
not aligned for disease severity. It is possible that many of the control cases were actually 
patients who had not yet developed diabetes, but had the genetic profile that would eventually 
lead them to develop diabetes. Incorrect labeling of targets is a known source of poor predictor 
performance. It would be worthwhile to redo this analysis with a larger sample size, with a 
higher proportion of case to control, and diabetic vs non-diabetic CP patients who are at 
comparable stages of disease. This may be better suited to find variants for subpopulations of CP 
patients who are prone to develop diabetes. 
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5.2.5 Comparison to other methods 
The PDTA is computationally much more intensive than regular decision tree implementations. 
Therefore, it is important to know if PDTA performs better than a regular decision tree package 
such as available in Scikit-learn76. Also, because of different theoretical underpinnings, different 
scoring functions can result in different optimal networks. To see how much PDTA is influenced 
by the choice of score, I compare performance of PDTA implementation with other 
implementations which use as score another Bayesian score, K2, and two information theoretic 
scores, AIC and MDL, across all 5 datasets (Table 39). PDTA is seen to outperform the regular 
decision tree on all 5 datasets. The choice of BDeu as the score for PDTA gives superior or 
equivalent performance compared to K2, AIC and MDL. 
 
Table 39: PDTA performance compared to other methods 
AUC 
 
PDTA 
AUC  (95% CI) 
Scikit-learn 
decision tree 
PDTA 
Using K2 
PDTA 
Using AIC 
PDTA    
Using MDL 
SD 0.989  (0.985-0.994) 0.851 0.987 0.982 0.987 
SBD 0.851  (0.816-0.887) 0.720 0.840 0.838 0.844 
SSD 0.602  (0.573-0.632) 0.563 0.597 0.590 0.583 
WE-CP-R 0.574  (0.528-0.620) 0.524 0.562 0.563 0.556 
WE-DB-R 0.617  (0.545-0.689) 0.532 0.621 0.565 0.570 
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6.0  CONCLUSIONS 
The PDTA was developed to enable discovery of patient-specific groups in complex diseases, 
where the discovery of rare variants is of great value. The results of evaluation on 5 different 
datasets, ranging from synthetic to real, shows that it is good at discovering rare variants as 
predictors. In the case of the CP-related datasets, several validated SNPs as well as unknown 
SNVs were identified that could be novel undiscovered disease variants that modulate or cause 
CP in conjunction with other variants. 
Our initial assumption was that the PDTA would have a separation in predictions from its 
two phases: the SDT was expected to be useful for population-wide characterization, while the 
PS path would give patient-specific groups. It turned out that the PS paths rarely improved over 
the personalization achieved by SDT. Patient-specific subgroups with rare variables as predictors 
surfaced within the SDT as a result of the Bayesian tree building method. This is nice, because it 
truly exemplifies a hierarchical view of a population that can be divided broadly (for presence or 
absence of a disease) but also stratified for how groups of patients with characteristic groups of 
variants can have individual disease risks, particularly valuable for uncovering rare variants that 
normally are not caught in large statistical studies. For example, in the dataset where chronic 
pancreatitis was used as the target phenotype, two subgroups emerged which included variants in 
diabetes-related genes. With the knowledge of a patient’s variant subgroup, precision medicine 
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can be applied for prognosis and treatment decisions targeting the pathways relevant to that 
individual’s biological sources of dysfunction. 
Although the PDTA does a good job of finding patient subgroups, it exhibits some signs 
of tension between generalizing to the population, and finding robust subgroups. The SSD was 
created specifically as a computational challenge to researchers for the discovery of rare variants. 
When PDTA was applied to SSD, the overall performance measures were not so good, with poor 
predictability for the majority of the population, but there were many subgroups within the tree 
that had high predictive power. When PDTA was applied to WE-DB, the presence of a much 
larger number of controls relative to diseased samples resulted in the largest predictive group to 
characterize the control population. The sample size and composition of the dataset can have a 
crucial effect on how well the PDTA balances the search for populations of interest. 
There were several rare variants implicated by PDTA with causal function in association 
with other rare and common variants. These can be novel discoveries to be tested further using 
methods such as candidate gene studies. When PDTA was applied to the CP cohort with diabetes 
as target phenotype, a patient subgroup was found to aggregate variants for insulin dysfunction 
with variants involved in pancreatic cancer. Diabetes and pancreatic cancer are both known to be 
eventual side effects of chronic pancreatitis, but there is no clear timeline of the development of 
these effects in relation to each other in the broader CP population. Moreover, there is evidence 
that suggests co-occurrence of risk factors for the development of diabetes and cancer in 
subpopulations of CP patients118,119. The variants discovered by PDTA could point to the 
mechanistic basis for such associations.   
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6.1 FINDINGS AND CONTRIBUTIONS 
PDTA provides (1) a prediction for the disease state, and (2) a set of variables in a patient-
specific subgroup that represent informative predictors for the individual patient of interest 
within the larger context of the diseased population, and may provide clues to the disease 
mechanisms active in that type of person. The set of probabilistic rules obtained from all 
individuals in the test set provides (1) a set of predictions for the population as a whole that is 
represented by the set, and (2) the union of features in all the rules provides clues to the disease 
mechanisms that are active in the entire population. 
The implementation of PDTA for genomic data, specifically, provides parsimonious 
genetic signatures containing rare variants that have the potential to be novel causal variants in 
subpopulations of patients with chronic pancreatitis. 
6.2 FUTURE WORK 
Observing the behavior of PDTA on several different datasets suggests many possible avenues of 
further improvement. 
6.2.1 Dimensionality Reduction 
In the case of large genomic datasets, their lower dimensional counterparts appeared to give 
better prediction results, while still selecting rare variants as predictors. It would be worth 
considering some form of dimensionality reduction to genomic datasets before application of the 
 109 
PDTA. Dimensionality reduction techniques are common in the biomedical domain. Many 
dimensionality reduction methods construct new features as a combination of variables, to create 
a more parsimonious set of variables. This would be unsuitable for the PDTA, which is trying to 
find rare variants. Any choice of dimensionality reduction should preserve interpretability in 
terms of the individual contributions of variants in the dataset, while providing enrichment of the 
variable space. 
6.2.2 Genotypic specificity 
In the development of PDTA, I described the genotypic adaptation to assignment of variable 
values, to mimic the idea of different kinds of genetic models (Section 5.1.3). This allows for 
variables in the model to assume more than one allelic value in calculating the branches 
emerging from that node. In some cases this may make sense: if a heterozygous variant has the 
same functional impact as a biallelic mutant variant, for example, they would have the same 
predictive effect for the disease phenotype. However, in some cases, the combination of 
functionally distinct conditions are not realistic. Consultation with a domain expert would help in 
refining this variable selection step such that only functionally meaningful combinations would 
contribute to tree growth. 
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